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We have constructed a recombinant herpes simplex virus type 1 (HSV-1) that simultaneously encodes
selected structural proteins from all three virion compartments—capsid, tegument, and envelope—fused with
autofluorescent proteins. This triple-fluorescent recombinant, rHSV-RYC, was replication competent, albeit
with delayed kinetics, incorporated the fusion proteins into all three virion compartments, and was comparable
to wild-type HSV-1 at the ultrastructural level. The VP26 capsid fusion protein (monomeric red fluorescent
protein [mRFP]-VP26) was first observed throughout the nucleus and later accumulated in viral replication
compartments. In the course of infection, mRFP-VP26 formed small foci in the periphery of the replication
compartments that expanded and coalesced over time into much larger foci. The envelope glycoprotein H (gH)
fusion protein (enhanced yellow fluorescent protein [EYFP]-gH) was first observed accumulating in a vesicular
pattern in the cytoplasm and was then incorporated primarily into the nuclear membrane. The VP16 tegument
fusion protein (VP16-enhanced cyan fluorescent protein [ECFP]) was first observed in a diffuse nuclear
pattern and then accumulated in viral replication compartments. In addition, it also formed small foci in the
periphery of the replication compartments which, however, did not colocalize with the small mRFP-VP26 foci.
Later, VP16-ECFP was redistributed out of the nucleus into the cytoplasm, where it accumulated in vesicular
foci and in perinuclear clusters reminiscent of the Golgi apparatus. Late in infection, mRFP-VP26, EYFP-gH,
and VP16-ECFP were found colocalizing in dots at the plasma membrane, possibly representing mature
progeny virus. In summary, this study provides new insights into the dynamics of compartmentalization and
interaction among capsid, tegument, and envelope proteins. Similar strategies can also be applied to assess
other dynamic events in the virus life cycle, such as entry and trafficking.
The herpes simplex virus type 1 (HSV-1) virion consists of
three different compartments, capsid, tegument, and envelope.
The icosahedral capsid has a diameter of 125 nm and contains
the virus genome, a double-stranded DNA of 152 kbp. The
structural basis of the capsid are the 162 capsomers, which
include 150 hexons and 12 pentons (47). The capsomers are
connected in groups of three by a complex formed with two
copies of VP23 and one copy of VP19c (47, 54, 68). The hexons
are composed of six molecules of the major capsid protein
VP5. Eleven of the 12 pentons are composed of five molecules
of VP5, while 1 of the 12, the so-called portal, is a cylindrical
structure of 12 molecules of UL6 (46). Also involved in capsid
assembly, but not physical components of the capsids, are the
scaffold polypeptides VP22a, VP21, and the serine protease,
VP24, which is required for capsid maturation (9, 26, 38, 51).
Six copies of VP26, a 12-kDa polypeptide encoded by the
UL35 gene, occupy the tips of each hexon and thus decorate
the surface of the capsid (42, 69). Although not essential for
virus replication in tissue culture, VP26 was demonstrated to
be important for infectious virus production in trigeminal gan-
glia (12). VP26 is a protein expressed later in the virus repli-
cation cycle after the onset of DNA replication and has been
demonstrated to have multiple phosphorylated forms (43).
VP26 has been shown to be recruited in an ATP-dependent
manner after pro-capsid formation (8). As it lacks a nuclear
localization signal (NLS), it must form complexes with NLS-
containing proteins, such as VP5 and VP22a, in order to spe-
cifically accumulate in the nucleus (52, 60).
The virus capsid is surrounded by an amorphous layer, the
so-called tegument. The tegument contains at least 15 virus-
encoded proteins in various copy numbers which play impor-
tant structural and functional roles during infection (32). One
major structural component of the tegument is VP16, a 54-kDa
protein encoded by the UL48 gene (63). Although VP16 is not
essential for viral DNA replication, its structural role in the
tegument is essential. Recombinants of HSV-1 that lack the
UL48 gene show impaired replication, a defect in DNA pack-
aging, and the absence of infectious virus progeny (63). VP16
is responsible for transcriptional regulation of immediate-early
(IE) genes and is also involved in the modulation of the activ-
ities of early and late virus genes (7, 48, 49). VP16 has been
shown to coimmunoprecipitate with virion host shutoff protein
(55), to cross-link into complexes with gB, gD, and gH (70),
* Corresponding author. Mailing address: Institute of Virology, Uni-
versity of Zurich, Winterthurerstrasse 266a, CH-8057 Zurich, Switzer-
land. Phone: 41 44 6358713. Fax: 41 44 6358911. E-mail: cornel.fraefel
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‡ A.P.O. and D.L.G. contributed equally to the work reported in this
article.
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and to copurify with UL47 (67) and with VP22 (16). Due to its
involvement in linking capsid and future envelope-associated
tegument proteins during virion formation, VP16 is absolutely
required for assembly of infectious virus (63) and plays essen-
tial roles in viral maturation and egress (24, 44).
The tegument is surrounded by the viral envelope, which is
a lipid membrane of cellular origin that contains at least 11
different viral glycoproteins. The glycoproteins are the major
antigenic determinants for the host-specific recognition, and
they are involved in cell entry, cell-to-cell spread, and immune
evasion. Glycoprotein H, the product of the UL22 gene, is a
110-kDa protein which is essential for infectivity (14) and
membrane fusion, but not for receptor binding (22, 25). Gly-
coprotein H must be coexpressed with gL in order for both
proteins to be properly processed, folded, and transported to
the virion envelope as well as the infected cell surface (33). The
gH/gL complex plays essential roles in viral penetration, cell-
to-cell spread, and syncytium formation (53). Both glycopro-
teins are conserved among the herpesviruses, although some
differences regarding assembly, structure, and intracellular
transport of the heterocomplex exist between individual her-
pesviruses (27, 33, 34, 50). Only very recently was it shown that
the simultaneous deletion of gH and gB results in a severe
deficit in nuclear egress leading to the accumulation of virions
in the perinuclear space, whereas the deletion of gH or gB
alone did not lead to a significant defect (19). One strategy to
investigate mechanisms of viral infection, replication, and as-
sembly is the fusion of viral proteins with autofluorescent pro-
teins (reviewed in reference 5). Many of the HSV-1 proteins
have been shown to maintain their functional activity when
fused with foreign polypeptides. Among these, a green fluo-
rescent protein (GFP)-VP26 fusion was demonstrated to be
incorporated into intranuclear capsids and mature virions,
where it was capable of interacting with VP5 while retaining its
autofluorescence (13). GFP-VP26 retained its biological activ-
ity during the replication cycle, as the recombinant virus rep-
licated at a rate comparable to that of wild-type (wt) virus (13).
A recombinant HSV-1 that expressed VP16 fused to GFP
(VP16-GFP) also showed normal replication kinetics and in-
corporation of the fusion protein into the virion (35). Similarly,
fusion of enhanced yellow fluorescent protein (EYFP) with gH
did not markedly alter gH functions, as the recombinant virus
was replication competent and showed stable autofluorescence
(39). The EYFP-gH fusion protein formed a stable heterocom-
plex with gL and was incorporated into the virion envelope as
well as cellular membranes (39).
In this study, we have constructed a recombinant HSV-1 that
simultaneously encodes the VP26 capsid protein fused with
monomeric red fluorescent protein (mRFP), the VP16 tegu-
ment protein fused with enhanced cyan fluorescent protein
(ECFP), and the gH envelope glycoprotein fused with EYFP.
This triple-fluorescent recombinant HSV-1, rHSV-RYC, was
replication competent and incorporated the autofluorescent
fusion proteins into all three virion compartments. Confocal
laser scanning microscopy (CLSM) of living infected cells re-
vealed new insights into the organization and dynamics of
HSV-1 infection and into the interactions between HSV-1
virion proteins. To our knowledge this is the first report of the
construction and live analysis of a recombinant virus encoding
three different autofluorescent fusion proteins.
MATERIALS AND METHODS
Cell culture and virus. BHK, Vero, and Vero 2-2 cells (56) were maintained
in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal
bovine serum (FBS). Penicillin G at 100 units/ml, 100 g/ml streptomycin, and
0.25 g/ml amphotericin B were added to all cell culture media. For culturing
Vero 2-2 cells, 500 g/ml G418 was included in addition.
HSV-1 strain F as well as the recombinant viruses were grown, and titers were
determined in Vero cells.
Construction of recombinant viruses. Recombinant HSV-1 encoding one
(rHSV-R or rHSV-48Y), two (rHSV-RYor rHSV-RC), or three (rHSV-RYC or
rHSV-RYC/2) different virion proteins fused with autofluorescent proteins were
generated by homologous recombination in Escherichia coli SW102 and galK
selection/counterselection (62) using a bacterial artificial chromosome (BAC)-
cloned HSV-1 strain F genome (pYEbac102; kindly provided by Y. Kawaguchi,
Tokyo Medical and Dental University, Japan) (59).
Electroporation and galK positive/negative selection. To prepare electrocom-
petent bacteria, 500 l of an overnight culture of E. coli SW102/YEbac102 was
diluted in 25 ml LB medium containing 12.5 g/ml chloramphenicol in a 50-ml
conical flask and grown at 32°C. When the optical density at 600 nm reached 0.6,
10 ml of the culture was transferred to another 50-ml conical flask and incubated
at 42°C in a shaking water bath. After exactly 15 min, the culture was briefly
cooled on ice, transferred into two 15-ml tubes, and pelleted for 5 min at 5,000
rpm and 0°C. The supernatant was removed, and the pellet was resuspended in
1 ml ice-cold H2O by gently swirling the tube on ice. Then, 9 ml of ice-cold H2O
was added, and the cells were pelleted again; this step was repeated once more.
After the second washing and centrifugation step, the supernatant was removed,
and the pellet (approximately 50 l) was kept on ice until electroporated with
PCR product (targeting cassettes). In a first step (galK selection), a PCR product
(see below) that contained the E. coli galK gene flanked by 50 nucleotides of
sequence homology to either side of the targeting locus on the virus genome
(VP26, gH, and VP16) (Fig. 1) was electroporated into 25 l of electrocompetent
E. coli SW102/YEbac102 cells in a 0.1-cm cuvette (Bio-Rad, Hercules, CA) at 25
F, 1.75 kV, and 200 . After electroporation, the bacteria were grown in 1 ml
LB medium for 1 h at 32°C and then washed twice with 1 M9 salts (37 mM
Na2HPO4, 22 mM KH2PO4, 19 mM NaCl) as follows: the culture was pelleted at
13,000 rpm for 15 s, resuspended in 1M9 salts, and pelleted again. The washing
step was repeated once more. After the second wash, the supernatant was
removed and the pellet was resuspended in 1 M9 salts before 100-l aliquots
of serial dilutions (1:10, 1:100, and 1:1,000) were plated on galactose minimal
medium plates (62) supplemented with 12.5 g/ml chloramphenicol to select
Gal recombinant colonies. After 2 to 3 days of incubation at 32°C, colonies
were picked and streaked on MacConkey galactose indicator plates to obtain
single bright pink/red Gal colonies. One or two of these colonies were picked
to prepare electrocompetent bacteria for the second recombination step, the
in-frame introduction of autofluorescent protein-coding sequences into VP26,
gH, or VP16 sequences and galK counterselection. For this, electrocompetent E.
coli SW102 cells containing the galK-modified YEbac102 were prepared as de-
scribed above and electroporated with PCR products (targeting cassettes; see
below) containing coding sequences of autofluorescent proteins flanked by the
same 50 nucleotides present on the galK PCR product that target the DNA to
homologous sequences in the virus genome (VP26, gH, and VP16). After elec-
troporation, the bacteria were recovered in 10 ml LB medium for 4.5 h at 32°C
and washed twice with 1 M9 salts, and serial dilutions were plated on minimal
medium plates containing glycerol as carbon source, leucine, biotin, and 2-deoxy-
galactose (DOG; Acros Organics, Geel, Belgium) for selection against galK (62).
After 3 days of incubation at 32°C, colonies were picked, and BAC DNA was
isolated and characterized by restriction endonuclease and Southern analysis.
PCR amplification and purification of targeting cassettes. Phusion polymer-
ase (Finnzymes, Espoo, Finland) and the following primers were used to amplify
the targeting cassettes: (i) mRFP-VP26 fusion, galK selection, ul35-galK-fw, 5-A
CAGCCCTCCCGACCGACACCCCCATATCGCTTCCCGACCTCCGGT
CCCG CCTGTTGACAATTAATCATCGGCA-3, and ul35-galK-rev, 5-CCAAGC
GCCCGGACGCTATCGGTGGTAACGGTGCTGGGGCGGTGAAATTGTCA
GCACTGTCCTGCTCCTT-3; mRFP-VP26 fusion, galK counterselection, ul35-rfp-
fw, 5-ACAGCCCTCCCGACCGACACCCCCATATCGCTTCCCGACCTCCG
GTCCCGATGGCCTCCTCCGAGGACGTC-3, and ul35-rfp-rev, 5-CCAAGCG
CCCGGACGCTATCGGTGGTAACGGTGCTGGGGCGGTGAAATTGGGC




CATGGTCAGCACTGTCCTGCTCCTT-3; EYFP-gH fusion, galK counterselec-
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ECFP fusion, galK selection, UL48-galK-fw, 5-TTCGAGTTTGAGCAGATGTTT
ACCGATGCCCTTGGAATTGACGAGTACGGTCCTGTTGACAATTAATCAT
CGGCA-3, and UL48-galK-rev, 5-GGTGACGGGAGGGGAAAACCCAGACGG
GGGATGCGGGTCCGGTCGCGCCCCTCAGCACTGTCCTGCTCCTT-3; VP16-
ECFP/EYFP fusion, galK counterselection, UL48-ECFP-fw, 5-TTCGAGTTTGAG
CAGATGTTTACCGATGCCCTTGGAATTGACGAGTACGGTGTGAGCA
AGGGCGAGGAGCTGTTC-3, and UL48-ECFP-rev, 5-GGTGACGGGAGG
GGAAAACCCAGACGGGGGATGCGGGTCCGGTCGCGCCCCTTACTTG
TACAGCTCGTCCATGCC-3. Sequence portions shown in italics are homolo-
gous to the galK gene. The following plasmids (10 ng) were used as templates:
pgalK for all galK selection/targeting cassettes (obtained from S. Warming,
National Cancer Institute, Frederick, MD) (62), pcDNA-mRFP-N1 (obtained
from U. F. Greber, University of Zurich, Zurich, Switzerland) for the VP26-
mRFP targeting cassette, and pECFP-N1 and pEYFP-N1 for amplification of
VP16-ECFP/EYFP and gH-EYFP targeting cassettes, respectively. The PCR
conditions were as follows: 94°C for 15 s, 60°C for 30 s, and 72°C for 1 min, for
30 cycles. After completion of the reaction, DpnI (10 U; New England Biolabs,
Allschwil, Switzerland) was added for digestion of the template for 2 h. The
DpnI-digested reaction mix was run on a 1% agarose gel, and the PCR product
was purified using a QIAQuick PCR purification kit (Qiagen, Hombrechtikon,
Switzerland) followed by ethanol precipitation. The DNA was resuspended in 40
l H2O, and an aliquot of 2 to 5 l (10 to 30 ng) was used for electroporation.
Excision of BAC sequences and isolation of recombinant HSV-1. To excise the
BAC DNA backbone and isolate recombinant viruses, 1.2  106 Vero 2-2 cells
(56) per 6-cm tissue culture plate were cotransfected with 0.2 g of plasmid p116,
which expresses Cre recombinase with an NLS (kindly provided by K. Tobler,
University of Zurich, Zurich, Switzerland), and 2 g of CsCl gradient-purified
recombinant HSV-1 BAC DNA using Lipofectamine (Invitrogen). After 2 to 3
days of incubation at 37°C, the supernatant was harvested and plaque purified
twice, and the excision of the BAC sequences was verified by PCR.
Virus replication assays. For the determination of growth kinetics, Vero cells
were inoculated at a multiplicity of infection (MOI) of 0.1 or 5 PFU per cell.
After 2 h of incubation at 37°C, 5% CO2, the cultures were washed three times
with PBS and then incubated with DMEM containing 2% FBS. Samples (cell
culture medium and cells) were removed after 0, 12, 24, 36, and 48 h. The cell
culture medium was removed from the cells and serially diluted to determine the
titers on Vero cells. The titers of cell-associated virus were determined on Vero
cells inoculated with serial dilutions of supernatants of cells prepared by three
cycles of freezing and thawing, followed by centrifugation at 1,900  g.
Determination of particle/PFU ratios. To determine the particle counts, virus
stocks with known titers (PFU/ml) were mixed with 204-nm-diameter latex beads
(Agar Scientific, Essex, United Kingdom) of known concentration, adsorbed
onto 300-mesh parlodion- and carbon-coated copper electron microscope grids
for 5 min at room temperature (RT), briefly washed with H2O, and negatively
stained with 2% sodium phosphotungstate, pH 7.4, for 1 min at RT. Samples
were examined in a transmission electron microscope (CM12; Philips, Eind-
hoven, The Netherlands), and the relative numbers of virus particles and latex
beads were determined, which allowed us to calculate the absolute numbers of
virus particles in the virus stocks.
Purification of virions. Virions were purified from BHK or Vero cells infected
at an MOI of 0.1 PFU with either wt HSV-1, rHSV-RYC, or rHSV-RYC/2.
When the cytopathic effect (CPE) was complete, the cultures were frozen and
thawed three times, and cell debris was removed by centrifugation for 10 min at
2,600 g and 4°C. Virions were purified through 60%, 30%, and 10% sucrose (in
PBS) gradients in Beckman Ultra-Clear 25- by 89-mm centrifuge tubes, which
were centrifuged for 2 h at 28,000 rpm and 4°C using a Beckman SW28 rotor.
The interface between the 30% and 60% sucrose layers was collected, diluted in
PBS, and ultracentrifuged for 1 h at 25,000 rpm and 4°C. Following resuspension
of the pellet in Hanks’ buffered saline solution, the virion stocks were frozen in
a dry ice-ethanol bath and stored at 80°C.
Immunoprecipitation, SDS-PAGE, Western analysis, and silver staining.
Vero cells (4  105 cells per well in a 12-well plate) were mock infected or
infected with either wt HSV-1, rHSV-RY, rHSV-RYC, or rHSV-RYC/2 at an
MOI of 1 PFU. When CPE was almost complete (between 24 and 48 h postin-
fection [p.i.]), the cells were washed with cold PBS and prepared for immuno-
precipitation or directly lysed with sodium dodecyl sulfate (SDS) loading buffer,
boiled for 5 min, and analyzed by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and Western blotting using the antibodies listed below. For immuno-
precipitation, the cells were lysed with 200 l of EBC170 lysis buffer (50 mM Tris
pH 8.0, 170 mM NaCl, 0.5% NP-40) supplemented with one tablet of protease
inhibitor cocktail (Complete, mini, EDTA-free; Roche Diagnostics, Rotkreuz,
Switzerland) per 10 ml. The cell extract was collected and immunoprecipitated
with the gH-specific monoclonal antibody (MAb) LP11 (kindly provided by A.
Minson and H. Browne, University of Cambridge, United Kingdom) (6) diluted
1:30 in EBC170. After 1 h at 4°C, complexes were allowed to attach to protein
A-Sepharose beads. After washing the beads four times with EBC170 buffer, the
LP11 MAb complexes were eluted from the beads by adding SDS loading buffer.
The samples were boiled for 5 min, and proteins were separated by SDS-PAGE
and transferred onto nylon membranes (Protran; Whatman, Bottmingen, Swit-
zerland). Nonspecific reactions were blocked by incubating the membranes for
1 h with PBS containing 5% skimmed milk and 0.3% Tween 20. Membranes were
then incubated for 1 h with antibodies against VP26 (rabbit polyclonal antibody
[PAb] diluted 1:1,000 in PBS, 0.3% Tween 20 [PBS-T]; kindly provided by A.
Helenius, ETH Zurich, Switzerland), VP16 (MAb LP1, diluted 1:500 in PBS-T;
FIG. 1. Construction of rHSV-RYC. (A) Representation of the
HSV-1 BAC (YEbac102) genome structure, showing the region con-
taining the UL35 gene. The galK expression cassette was inserted into
the UL35 gene through homologous recombination (HR) and selec-
tion for Gal recombinants (rHSVBAC35galK). GalK was then re-
placed by mRFP coding sequences by HR and counterselected for
Gal recombinants (rHSVBAC35R). The same procedure was used
for the fusion of EYFP with the UL22 gene on the rHSVBAC35R
genome (B) and for the fusion of ECFP with the UL48 gene on rHSV
BAC35R22Y (C). The BAC sequences were removed by the Cre/loxP
recombination system (Cre), resulting in the recombinants HSV-1
rHSV-R, rHSV-RY, and rHSV-RYC. TRL, terminal repeat of the
long segment; UL, unique long segment; IRL, internal repeat of the
long segment; IRS, internal repeat of the short segment; US, unique
short segment; TRS, terminal repeat of the short segment.
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kindly provided by A. Minson and H. Browne, University of Cambridge, United
Kingdom) (41), GFP (MAb JL-8BD, diluted 1:8,000 in PBS-T; Clontech, Saint-
Germain-en-Laye, France), ICP4 (MAb, diluted 1:10,000 in PBS-T; Advanced
Biotechnologies, Columbia, MD), ICP8 (MAb clone 10A3, diluted 1:10,000 in
PBS-T; Abcam, Cambridge, United Kingdom), and VP22 (rabbit PAb AGV031,
diluted 1:10,000 in PBS-T; kindly provided by G. Elliott, Marie Curie Research
Institute, Oxted, United Kingdom). After washing, the membranes were incu-
bated with rabbit anti-mouse immunoglobulin G (IgG)–horseradish peroxidase
(HRP) (1:10,000 in PBS-T; Sigma-Aldrich, Buchs, Switzerland) or goat anti-
rabbit IgG–HRP (1:10,000 in PBS-T; Sigma-Aldrich, Buchs, Switzerland). Target
proteins were visualized by enhanced chemiluminescence (ECL Western blotting
analysis system; GE Healthcare, Zurich, Switzerland) and autoradiography
(Lumi-film chemiluminescent detection film; Roche Diagnostics, Rotkreuz, Swit-
zerland). A molecular weight standard (BenchMark prestained ladder; GIBCO,
Invitrogen, Basel, Switzerland) was used to determine the sizes of the protein
bands. Silver staining of gels was performed using the Bio-Rad silver stain kit
(Bio-Rad, Hercules, CA) according to the manufacturer’s manual.
CLSM. CLSM was performed on a Leica TCS SP2 AOBS confocal laser
scanning microscope (Leica Microsystems, Wetzlar, Germany) equipped with an
incubation chamber (THE BOX; Live Imaging Services, Reinach, Switzerland),
a temperature control device (THE CUBE; Live Imaging Services, Reinach,
Switzerland), and a gas mixer (THE BRICK; Live Imaging Services, Reinach,
Switzerland). The settings for the individual fluorophores were as follows: 4,6-
diamidine-2-phenylindole (DAPI), excitation at 405 nm and recording at 415 to
480 nm; ECFP, excitation at 458 nm and recording at 468 to 510 nm; fluorescein
isothiocyanate (FITC), excitation at 488 nm and recording at 498 to 570 nm;
EYFP, excitation at 514 nm and recording at 520 to 550 nm; mRFP/Atto590/
Alexa Fluor 594 (AF594), excitation at 594 nm and recording at 604 to 700 nm.
In order to avoid channel overlap, blue and red channels were recorded simul-
taneously while the yellow/green channels were recorded separately. The images
shown in Fig. 7 and 8, below, were deconvolved with a blind deconvolution
algorithm using the Huygens Essential 2.6.0p1 software (Scientific Volume Im-
aging, Hilversum, The Netherlands). Image processing was done with Imaris
5.0.1 (Bitplane AG, Zurich, Switzerland) and Adobe Photoshop CS 8.0.1 soft-
ware. The detailed procedures were as follows.
(i) High-resolution CLSM of live or fixed, infected cells. Vero cells were
seeded on Lab-Tek four-well chambered coverglasses (Nalge Nunc Interna-
tional, Rochester, NY) at 105 cells/well. On the following day, the cells were
washed once with cold (4°C) DMEM and incubated for 15 min at 4°C, and the
DMEM was replaced with cold (4°C) virus inoculum at the MOIs described in
the figure legends. The viruses were then allowed to adsorb to the cells for 1 h
at 4°C with gentle shaking. Subsequently, the virus inoculum was replaced with
warm (37°C) Iscove’s modified Dulbecco’s medium (GIBCO, Invitrogen, Basel,
Switzerland) supplemented with 25 mM HEPES and 2% FBS, and the cells were
incubated at 37°C, 5% CO2. At the indicated times after infection (temperature
shift), live cells were observed by CLSM in a humidified atmosphere at 37°C,
5%CO2. Where mentioned in the text below, the cells were fixed with 3.7%
formaldehyde in PBS for 15 min at RT prior to microscopy.
(ii) Time-lapse CLSM of live, infected cells. Vero cells were seeded into
35-mm glass-bottom dishes (MatTek, Ashland, MA) at 5 105 cells/dish. On the
following day, the cells were infected with rHSV-RY or rHSV-RYC diluted in
DMEM at the MOIs described in the text below. The viruses were allowed to
adsorb for 2 h at 37°C, 5% CO2. The cells were then washed with PBS, overlaid
with Iscove’s modified Dulbecco’s medium supplemented with 25 mM HEPES
and 2% FBS, and incubated at 37°C, 5% CO2. At the indicated time, live cells
were observed by CLSM in a humid atmosphere at 37°C, 5% CO2. Images were
recorded at intervals of 15 to 25 min.
Immunofluorescence. Vero cells were seeded on round 12-mm coverglasses in
24-well plates at 105 cells/well. On the following day, the cells were washed with
PBS and infected with wt HSV-1 or rHSV-RY diluted in DMEM at the MOIs
described in the figure legends. The viruses were allowed to adsorb for 1 to 2 h
at 37°C, 5% CO2. The cells were then washed with PBS, overlaid with DMEM
supplemented with 2% FBS, and incubated at 37°C, 5% CO2. At the indicated
time points, the cells were washed once with cold PBS and fixed with 3.7%
formaldehyde in PBS for 15 min at RT, and the fixation was stopped with 0.1 M
glycine in PBS for 5 min at RT. Immunofluorescence staining, DAPI staining,
and embedding of cells were performed as described previously (29) except that
the cells were permeabilized with 0.2% Triton X-100 in PBS for 15 min at RT
and that 0.2 mg/ml human IgG (Sigma-Aldrich, Buchs, Switzerland) was in-
cluded in the blocking solution when cells were stained with antibodies of rabbit
origin. Primary antibodies were used at the following dilutions: anti-HSV-1 ICP8
MAb 7381 (kindly provided by R. D. Everett, MRC Virology Unit, Glasgow,
United Kingdom), 1:500 (see Fig. 6C, below) or 1:1,000 (see Fig. 6D, below);
anti-HSV-1 gH MAb LP11, 1:3; anti-HSV-1 VP16 MAb LP1, 1:3 (see Fig. 8A,
below) or 1:200 (see Fig. 8D, below); rabbit anti-HSV-1 VP26 PAb VP26/C
(kindly provided by P. Desai, Johns Hopkins University, Baltimore, MD) (12),
1:400. Secondary antibodies were used as follows: F(ab)2 fragment of goat
anti-rabbit IgG(HL)–AF594 (Molecular Probes, Invitrogen, Basel, Switzer-
land), 1:200; goat anti-rabbit IgG(HL)–FITC (Southern Biotechnology, Bir-
mingham, AL), 1:100; goat anti-mouse IgG(HL)–AF594 (Molecular Probes,
Invitrogen, Basel, Switzerland), 1:200; Fab fragment of goat anti-mouse
IgG(HL)–FITC (Jackson ImmunoResearch, West Grove, PA), 1:100.
FISH. Infection with wt HSV-1 and immunofluorescence staining for VP26
were performed as described above. Fluorescent in situ hybridization (FISH) was
performed as described previously (18) with the following modifications: (i) cells
were fixed with precooled methanol for 10 min at 20°C; (ii) immunofluores-
cence staining was performed before the hybridization step; (iii) fluorescent
labeling of BAC-cloned HSV-1 DNA (YEbac102) was performed with an
Atto590 nick translation labeling kit according to the manufacturer’s manual
(Jena Bioscience, Jena, Germany).
Electron microscopy. Vero cells were grown on sapphire disks for 2 days prior
to infection with rHSV-RYC. After 24 h, cells were fixed with 0.25% glutaral-
dehyde for 30 min and then frozen in a high-pressure freezer (HPM010; BAL-
TEC Inc., Balzers, Liechtenstein) as previously described (37). The sapphire
disks carrying the frozen cells were transferred into a freeze-substitution unit (FS
7500; Boeckeler Instruments, Tucson, AZ) precooled to 88°C for substitution
with acetone and subsequent fixation with 0.25% glutaraldehyde and 0.5%
osmium tetroxide at temperatures between 30°C and 2°C as previously de-
scribed in detail (64) and embedded in Epon at 4°C. Sections of 50 to 60 nm were
analyzed in a transmission electron microscope (CM12; Philips, Eindhoven, The
Netherlands) equipped with a slow-scan charge-coupled-device camera (Gatan,
Pleasanton, CA) at an acceleration voltage of 100 kV.
RESULTS
Construction of a recombinant HSV-1 encoding mRFP-
VP26, VP16-ECFP, and EYFP-gH fusion proteins. The goal of
this study was to construct and characterize a recombinant
HSV-1 that simultaneously encodes selected structural pro-
teins from all three virion compartments fused with autofluo-
rescent proteins, in particular, capsid protein VP26 fused with
mRFP, tegument protein VP16 fused with ECFP, and enve-
lope glycoprotein H fused with EYFP. This triple-fluorescent
recombinant HSV-1 was constructed via homologous recom-
bination in E. coli using a BAC-cloned HSV-1 strain F genome
(pYEbac102) (59) and the galK positive/negative selection
method (62) as described in Materials and Methods. Briefly, in
a first step, a DNA fragment containing the galK expression
cassette flanked by homology arms that target the cassette
between codons 1 and 5 of the VP26 coding sequences was
electroporated into E. coli SW102 cells that contained the
pYEbac102 HSV-1 BAC DNA. Gal-positive recombinant bac-
teria were selected on galactose minimal medium plates. BAC
DNA prepared from these clones was characterized by restric-
tion endonuclease analysis (not shown), and one clone
(rHSVBAC35galK) was selected for the second recombination
step. For the second step, the galK expression cassette was
replaced by electroporating a DNA fragment containing the
mRFP expression cassette, again flanked by the homology
arms that facilitate the in-frame insertion of mRFP coding
sequences between codons 1 and 5 of the VP26 coding se-
quences, into E. coli SW102/rHSVBAC35galK. After galK
counterselection with DOG, Gal-negative colonies were
picked, BAC DNA was prepared and characterized by restric-
tion endonuclease analysis (not shown), and one clone (rHSV
BAC35R; Fig. 1A) was selected for further manipulation. The
subsequent fusion of gH with EYFP (rHSVBAC35R22Y; Fig.
1B) and VP16 with ECFP (rHSVBAC35R22Y48C; Fig. 1C)
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was performed using the same galK positive/negative selection
procedure described above and in Materials and Methods. The
final recombinant, rHSVBAC35R22Y48C, contained codons 1
to 225 of mRFP fused to codons 5 to 108 of VP26, codons 2 to
239 of EYFP inserted between codons 6 and 9 of gH, and
codons 1 to 489 of VP16 fused to codons 2 to 239 of ECFP.
Two additional recombinant HSV-1 BACs were constructed
that contained either codons 1 to 489 of VP16 fused to codons
2 to 239 of EYFP (rHSVBAC48Y) or codons 1 to 225 of
mRFP fused to codons 5 to 108 of VP26 and codons 1 to 489
of VP16 fused to codons 2 to 239 of ECFP (rHSVBAC35R
48C). A second triple-fluorescent recombinant HSV BAC,
rHSVBAC35R22Y48C/2, was created by introducing codons 2
to 239 of EYFP between codons 6 and 9 of gH in rHSVBAC
35R48C. The two triple-fluorescent HSV BACs, rHSVBAC
35R22Y48C and rHSVBAC35R22Y48C/2, encode the same
fusion proteins, but these were inserted in different orders. To
confirm that the recombinations had occurred as expected,
BAC DNA was analyzed by restriction endonuclease digestion
and Southern blot analysis (not shown). Finally, to rescue re-
combinant viruses and release the virus genome from the BAC
backbone, recombinant HSV-1 BAC DNA was cotransfected
with a Cre recombinase-expressing plasmid, p116, into mam-
malian cells (Fig. 1). Progeny virus was harvested after 2 to 3
days and plaque purified twice, and the excision of the BAC
sequences was confirmed by PCR analysis (not shown). The
recombinant viruses constructed and used in this study were
designated as follows: rHSV-R (mRFP-VP26), rHSV-48Y
(VP16-EYFP), rHSV-RY (mRFP-VP26 and EYFP-gH),
rHSV-RC (mRFP-VP26 and VP16-ECFP), rHSV-RYC (mRFP-
VP26, EYFP-gH, and VP16-ECFP), and rHSV-RYC/2 (mRFP-
VP26, EYFP-gH, and VP16-ECFP). The two triple-fluorescent
recombinants, rHSV-RYC and rHSV-RYC/2, produced compa-
rable titers and showed identical patterns of fluorescence in in-
fected cells (not shown).
Synthesis of autofluorescent fusion proteins in infected
cells. To verify that the recombinant viruses expressed the fluo-
rescent fusion proteins, Vero cells were mock infected or infected
with either wt HSV-1, rHSV-RY, or rHSV-RYC at an MOI of 1
PFU per cell. When the CPE was approximately 90%, cells were
harvested and analyzed. The 90% CPE was reached approxi-
mately 24 h p.i. for the wt virus and 48 h p.i. for the recombinant
virus, consistent with delayed replication kinetics of the recombi-
nant viruses (see Fig. 3, below). Western blotting with a rabbit
anti-VP26 PAb (kindly provided by A. Helenius, ETH, Zurich,
Switzerland) detected the 12-kDa VP26 protein from wt HSV-1-
infected cell lysates. In the lysates of rHSV-RY- or rHSV-RYC-
infected cells, the 12-kDa VP26 was not detected but was re-
placed with a band of approximately 50 kDa, which corresponds
to the size expected for the mRFP-VP26 fusion protein (Fig. 2A).
FIG. 2. Expression of fluorescent fusion proteins in infected cells. Vero cells were mock infected (m) or infected with either wt HSV-1 (wt),
rHSV-RY (RY), rHSV-RYC (RYC), or rHSV-RYC/2 (RYC/2) at an MOI of 1 PFU and harvested when the CPE was approximately 90%. Cell
lysates were analyzed by SDS-PAGE followed by Western blotting with antibodies against VP26 (A), VP16 (B), GFP (C), ICP4 (F), and ICP8 (G).
For detection of gH and EYFP-gH, cell lysates were immunoprecipitated with a gH-specific antibody followed by SDS-PAGE and silver staining
(D) or Western blotting with a GFP-specific antibody (E). Arrows indicate the mRFP-VP26, VP16-ECFP, and EYFP-gH fusion proteins, as well
as the wt VP26, VP16, gH, ICP4, and ICP8 proteins. The arrowheads in panels D and E point to a band that likely represents the EYFP-gH
precursor. Sizes of molecular weight standards are indicated.
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The band intensity of the wt 12-kDa VP26 protein was consis-
tently weaker than that of the 50-kDa mRFP-VP26 fusion pro-
tein. The reason for this might be that the relatively small VP26
protein adsorbed less well to the nitrocellulose membrane than
the larger fusion protein.
Western blotting with the anti-VP16 MAb LP1 (41) detected
the VP16 protein in lysates of cells infected with either wt
HSV-1 or rHSV-RY. In rHSV-RYC-infected cell lysates, how-
ever, the native VP16 was replaced by a band of approximately
100 kDa, which was also detected by the GFP-specific MAb
JL-8BD (Fig. 2B and C). As the GFP-specific antibody reacts
not only with GFP and ECFP but also with EYFP, a band of
approximately 140 kDa was visible in both rHSV-RY- and
rHSV-RYC-infected cell lysates which represented the
EYFP-gH fusion protein (Fig. 2C, left panel). Of note is that
the levels of the EYFP-gH fusion protein appeared to be
higher in rHSV-RY- than in rHSV-RYC-infected cells. We
therefore compared the EYFP-gH expression level of rHSV-
RYC to that of the independently constructed triple-labeled
virus, rHSV-RYC/2, as well as to rHSV-RY. As shown in Fig.
2C (right panel), the ratios between EYFP-gH and VP16-
ECFP were comparable for both triple-labeled viruses. In ad-
dition, in this experiment, the total amounts of EYFP-gH ap-
peared similar for the double- and triple-labeled viruses. The
reason for the fairly low levels of EYFP-gH detected in some
experiments therefore appears to be due to variations in the
efficiency of infection between different experiments, rather
than due to an inherent inability of the triple-colored viruses to
express normal amounts of EYFP-gH.
To compare the expression levels of gH from wt HSV-1 and
those of EYFP-gH from the recombinant viruses, cell lysates
were immunoprecipitated with the gH-specific MAb LP11 (6),
which binds to a conformational epitope of gH, followed by
SDS-PAGE and silver staining of the gel (Fig. 2D). A band
corresponding to the molecular mass of gH (110 kDa) was
visible for wt HSV-1 but was replaced with bands correspond-
ing to the molecular mass of EYFP-gH (140 kDa) in the
samples of the recombinant viruses. The levels of gH appeared
to be higher for wt HSV-1 and for rHSV-RY than for rHSV-
RYC. To confirm expression of the EYFP-gH fusion protein,
lysates were first immunoprecipitated with the gH-specific
MAb LP11 and then analyzed by SDS-PAGE and Western
blotting. The GFP-specific antibody detected the approxi-
mately 140-kDa EYFP-gH fusion protein in both rHSV-RY-
and rHSV-RYC-infected cell lysates (Fig. 2E). Of note is that
the levels of EYFP-gH were similar in this setting. Interest-
ingly, in rHSV-RY-infected cell lysates but not in rHSV-RYC-
infected cell lysates, a slightly smaller band was also visible,
which likely represents the EYFP-gH precursor (30) (Fig. 2E).
The accumulation of the EYFP-gH precursor might be a con-
sequence of the higher total levels of EYFP-gH of rHSV-RY
resulting in incomplete processing of the precursor, while the
lower EYFP-gH levels expressed by rHSV-RYC may be com-
pletely processed into the mature form. The GFP-specific an-
tibody also detected the VP16-ECFP fusion protein in rHSV-
RYC-infected and LP11-immunoprecipitated cell lysates (Fig.
2E), which is consistent with an earlier finding that gH can
coimmunoprecipitate with VP16 (31). An alternative explana-
tion, however, could be that VP16-ECFP and EYFP-gH coim-
munoprecipitate because GFP-derived proteins can undergo
weak dimerization (57, 65, 66).
We also compared the accumulation of the HSV-1 IE pro-
tein ICP4 and the early protein ICP8 among wt HSV-1 and the
recombinants. While ICP4 (Fig. 2F) accumulated to compara-
ble levels in cells infected with either wt HSV-1, rHSV-RY, or
rHSV-RYC, the levels of ICP8 (Fig. 2G) were reduced in cells
infected with the recombinant viruses. In conclusion, these
results demonstrated that the fusion proteins mRFP-VP26,
VP16-ECFP, and EYFP-gH were expressed in infected cells
with ongoing compromised levels of gene expression.
Growth kinetics of autofluorescent recombinant HSV-1. We
assessed the growth properties of recombinants that expressed
the mRFP-VP26 fusion alone or coexpressed two or three of
the fusion proteins. In the first set of experiments, Vero cells
were infected at a low MOI (0.1 PFU) with either wt HSV-1,
rHSV-R, rHSV-48Y, rHSV-RY, rHSV-RC, or rHSV-RYC,
and cultures were harvested at 12, 24, 36, and 48 h p.i. as
described in Materials and Methods. Virus yields in both cell
culture supernatant (Fig. 3A) and cells (Fig. 3B) were titrated
separately (PFU/ml). The growth properties of the recombi-
nant viruses compared to wt HSV-1 can be summarized as
follows: (i) the kinetics of virus release was delayed for recom-
binants rHSV-RY and rHSV-RYC, while all the other recom-
binants showed kinetics similar to that of wt HSV-1 (Fig. 3A);
(ii) in the supernatant, the final titers of the recombinant
viruses were reduced 2.6-fold (rHSV48Y) to 40-fold (rHSV-
RYC) at 48 h p.i; (iii) in the cell pellet, the final titers of the
recombinant viruses were reduced 7.7-fold (rHSV-RY) to 62-
fold (rHSV-RC) at 48 h p.i. While it appeared that the fusion
of EYFP to gH contributed to the delayed kinetics of virion
release of rHSV-RY and rHSV-RYC (Fig. 3A), the contribu-
tion of the individual fusions to the reduced final titers was less
obvious; specifically, the fusion of EYFP to VP16 alone
(rHSV-48Y) had the weakest effect on the final titers, and all
other recombinants, whether single, double, or triple labeled,
showed similar final titers in the supernatants (Fig. 3A).
In a second set of experiments, we compared the growth
properties of rHSV-RYC and wt HSV-1 at a high MOI (5
PFU) (Fig. 3C and D). Under these conditions, the growth
deficit of the triple-labeled recombinant was less pronounced.
Although the delayed kinetics of virus production was still
observed, the final titers at 48 h p.i. differed only by a factor of
5.8 in the supernatant and a factor of 5.6 in the pellet. These
findings suggest that the growth deficit of rHSV-RYC can be
partially overcome by infection at high MOI, which obviates
the need for efficient cell-to-cell spread.
To further characterize the growth properties of the recom-
binant viruses, we determined the particle/PFU ratios of two
recombinants, rHSV-RY and rHSV-RYC, as well as wt
HSV-1. We observed particle/PFU ratios of 68  49 (mean 
standard deviation) for rHSV-RY, 26  19 for rHSV-RYC,
and 1.3  0.9 for wt HSV-1, indicating that the recombinant
viruses were on average 20- to 50-fold less infectious than the
wt virus, a finding which at least partially explains the reduced
titers in the recombinant virus stocks.
In summary, the recombinant viruses showed reduced titers
both in the supernatant as well as in the pellet, with more
pronounced reductions at low than at high MOI. While the
fusion of EYFP to gH seemed to contribute to a delay in the
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kinetics of virion release, there was no clear correlation be-
tween the number of tagged virion proteins and the reduction
in titer. Finally, the recombinant viruses did not seem to have
a specific deficit at the level of virion egress, since the differ-
ences between the wt virus and the recombinants were com-
parable in the supernatant and the pellet. The data rather
suggest that the kinetics of recombinant virus replication was
delayed.
Incorporation of autofluorescent fusion proteins into the
virion. To confirm that all three fusion proteins were incorpo-
rated into the virion, wt HSV-1 virions and rHSV-RYC virions
were prepared by sucrose gradient centrifugation and analyzed
for the presence of the recombinant proteins. Western blotting
with the VP26-specific PAb revealed the 12-kDa VP26 in wt
HSV-1 virions and the 50-kDa mRFP-VP26 fusion protein in
rHSV-RYC virons (Fig. 4A). Similar to the observations made
in Fig. 2A, the band intensity of the wt VP26 protein was
weaker than that of the mRFP-VP26 fusion protein. As pre-
viously mentioned, this difference might be due to different
efficiencies of adsorption to the nitrocellulose membrane, since
it is unlikely that the fusion protein is incorporated more effi-
ciently into the virions than the wt protein. Similar observa-
tions were also made in a previous report (45). In order to
obtain a visible band for wt VP26, a doubled amount of wt
virions was loaded for the blot shown in Fig. 4A. Western
blotting with the VP16-specific MAb revealed the presence of
VP16 in the wt virions and VP16-ECFP in the rHSV-RYC
virions, the amounts of which appeared comparable (Fig. 4B).
The VP16-ECFP fusion protein, but not wt VP16, could also
be detected with the GFP-specific MAb (Fig. 4C). As expected,
the anti-GFP MAb also detected the EYFP-gH fusion protein
(Fig. 4C). As noted in Fig. 2, the ratio of EYFP-gH to VP16-
ECFP was quite variable between individual experiments (Fig.
2C, compare left and right panels). To detect gH from wt
HSV-1 and EYFP-gH from rHSV-RYC, virion proteins were
immunoprecipitated with the gH-specific MAb LP11 followed
by SDS-PAGE and silver staining. The results shown in Fig. 4D
demonstrate the presence of gH in wt virions and EYFP-gH in
rHSV-RYC virions. Again, it appeared that the level of gH was
higher in the wt virus than in with the recombinant. As ex-
pected, immunoprecipitation of virion lysates with LP11 fol-
lowed by Western blotting with the anti-GFP MAb detected
the EYFP-gH fusion protein but not the wt gH (Fig. 4E). As
previously noted (Fig. 2E), VP16-ECFP coimmunoprecipi-
tated with EYFP-gH (Fig. 4E). Staining for the VP22 tegu-
ment protein confirmed that comparable amounts of virions
were loaded on the gels (Fig. 4F). Taken together, these results
demonstrate that all three fusion proteins, mRFP-VP26,
VP16-ECFP, and EYFP-gH, are indeed incorporated into the
virus particle, although the amounts of incorporated EYFP-gH
were lower than those of wt gH.
Dynamics of compartmentalization of mRFP-VP26, VP16-
ECFP, and EYFP-gH in infected cells. Next, we monitored the
localization of mRFP-VP26, VP16-ECFP, and EYFP-gH in
FIG. 3. Growth kinetics of recombinant HSV-1 and wt HSV-1. Vero cells were infected with MOIs of 0.1 (A and B) or 5 (C and D) PFU of
either a recombinant HSV-1 (rHSV-R, rHSV-RY rHSV-RYC, rHSV-RC, or rHSV-48Y) or wt HSV-1, and progeny virus was harvested from the
cell culture medium (A and C) or from the cells (B and D) at 0, 12, 24, 36, and 48 h p.i. Titers are expressed as PFU per ml. The titers represent
means from three experiments. Error bars represent standard deviations.
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infected cells. For this, Vero cells were plated onto chambered
coverglasses and infected with rHSV-RYC, and live cells were
examined by CLSM at various times after infection. In the first
hours postinfection, small fluorescent foci were detected on
the surface of the cells and within the cytoplasm (Fig. 5a to d).
Some foci show colocalizations of ECFP, EYFP, and mRFP
signals, suggesting that they represent intact virions from the
virus inoculum (Fig. 5a to d, insets). De novo protein synthesis
was first observed at 6 h p.i. for VP16-ECFP, which was found
diffusely in the nucleus with accumulation in very early viral
replication compartments (RCs) (Fig. 5e and h). At 8 h p.i.,
VP16-ECFP was present in mature nuclear RCs as well as in
the cytoplasm, where it was found in a diffuse pattern with
accumulation in some small perinuclear foci (Fig. 5i and l). At
this time, expression of EYFP-gH and mRFP-VP26 also be-
came apparent. In particular, EYFP-gH was found diffusely in
the cytoplasm with some accumulation in a vesicular pattern
around the nucleus (Fig. 5j and l), while mRFP-VP26 was
found in small microfoci which were distributed throughout
the nucleus with accumulation in viral RCs (Fig. 5k and l).
These small microfoci displayed a high mobility within the
nucleus (not shown), reflecting active movement of nuclear
capsids (21). The localization of the VP26 and VP16 fusion
proteins to RCs was confirmed by staining rHSV-R- and
rHSV-48Y-infected cells for ICP8, a marker for RCs (Fig. 6C
and D). Between 10 and 16 h p.i., VP16-ECFP was predomi-
nantly found in the viral RCs as well as in small foci in their
periphery. In addition, the cytoplasmic VP16-ECFP accumu-
lation became more intense, with a pronounced recruitment of
VP16-ECFP to the plasma membrane, where it was found in a
dot-like pattern (Fig. 5m and p). At this stage, EYFP-gH was
still prominent in the cytoplasm but now strongly accumulated
in the nuclear membrane (Fig. 5n and p). Microfoci of mRFP-
VP26 were still observed in the nucleus, but in addition,
mRFP-VP26 was also observed in much larger foci which pref-
erentially formed in the periphery of the RCs, but it did not
colocalize with the small VP16-ECFP foci (Fig. 5o and p).
These large foci have previously been suggested to correspond
to sites of capsid assembly, so-called assemblons (13). Between
18 and 24 h p.i., two additional patterns became apparent.
FIG. 4. Incorporation of fluorescent proteins into virions. Purified wt HSV-1 (wt), rHSV-RY (RY), rHSV-RYC (RYC), and rHSV-RYC/2
(RYC/2) were analyzed by SDS-PAGE followed by Western blot analysis with antibodies specific for VP26 (A), VP16 (B), GFP (C), and VP22
(F). For detection of gH and EYFP-gH, virion proteins were immunoprecipitated with a gH-specific antibody and analyzed by SDS-PAGE
followed by silver staining (D) or Western blotting with a GFP-specific antibody (E). The corresponding fusion proteins mRFP-VP26, VP16-ECFP,
and EYFP-gH, as well as the wt VP26, VP16, gH, and VP22 proteins are indicated. Unspecific bands are marked by asterisks. Sizes of molecular
weight markers are shown.
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FIG. 5. High-resolution CLSM of living rHSV-RYC-infected cells. Vero cells were infected with an MOI of 18 PFU, and live cells were
observed by CLSM with settings specific for ECFP (VP16-ECFP fusion protein), EYFP (EYFP-gH fusion protein), and mRFP (mRFP-VP26
fusion protein). The thin gray lines in panels a to d mark the contours of the nucleus. The insets in panels a to d show a magnification of the sector
denoted by the white square. The filled arrowheads within the insets point to colocalizations of ECFP, EYFP, and mRFP signals. Arrows, early
RCs; filled triangle, VP16-ECFP foci in periphery of RCs; open triangles, large mRFP-VP26 and VP16-ECFP foci in periphery of nuclei; filled
diamonds, asymmetric, perinuclear accumulation of VP16-ECFP and mRFP-VP26. Images represent single z stacks of the cells.
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First, the majority of the VP16-ECFP was consistently re-
cruited out of the nucleus into the cytoplasm. Specifically, it
was found accumulating in an asymmetric, perinuclear pattern
reminiscent of the Golgi complex, where it often colocalized
with mRFP-VP26 and associated with EYFP-gH (Fig. 5q to t).
Second, in a subset of cells, VP16-ECFP was recruited into the
large mRFP-VP26 foci in the periphery of the nucleus, while
EYFP-gH remained in a pronounced perinuclear pattern (Fig.
FIG. 6. High-resolution CLSM of rHSV-RYC-infected cells and rHSV-R- and rHSV-48Y-infected cells stained for ICP8. (A) Vero cells were
infected with rHSV-RYC, and living cells were observed by CLSM as described for Fig. 5. The images show a high magnification of a protrusion
of the plasma membrane (top of picture). The arrows point to foci in which all three fusion proteins colocalize. The insets show magnifications
of these foci. (B) Vero cells were infected with rHSV-RYC, and fixed cells were observed by CLSM as described for panel A. (C) Vero cells were
infected with rHSV-R at an MOI of 10 PFU, fixed at 12 h p.i., and stained with the anti-ICP8 MAb 7381 and a FITC-conjugated secondary
antibody, as well as DAPI. The cells were observed by CLSM with settings specific for DAPI, FITC (ICP8), and mRFP (mRFP-VP26 fusion
protein). (D) Vero cells were infected with rHSV-48Y at an MOI of 10 PFU and stained as described for panel C, except that an AF594-conjugated
secondary antibody was used. The cells were observed by CLSM with settings specific for DAPI, EYFP (VP16-EYFP fusion protein), and AF594
(ICP8). Images in panels A to D represent single z stacks of the cells.
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5u to x). Finally, at these late time points, the dot-like accu-
mulations of VP16-ECFP at the plasma membrane consis-
tently colocalized with EYFP-gH and mRFP-VP26 (Fig. 5q to
t), suggesting that they reflect the accumulation of progeny
virus at the plasma membrane. This possibility was further
investigated by high-magnification CLSM of the plasma mem-
brane, which, as previously described, often formed pro-
nounced plasma membrane protrusions (35) (Fig. 6A and B).
On such plasma membrane protrusions, we observed a very
strong association of VP16-ECFP and mRFP-VP26 (Fig. 6A,
panel d) as well as a somewhat looser association of EYFP-gH
with mRFP-VP26 and VP16-ECFP (Fig. 6A, panels e and f).
The looser association of EYFP-gH with mRFP-VP26 and
VP16-ECFP is probably due to the fact that we observed living
cells and that while the ECFP and the mRFP channels were
recorded simultaneously, the EYFP channel was recorded sep-
arately, thus explaining the observed differences in the degree
of colocalization. Indeed, the association between the three
signals was more pronounced in fixed cells (Fig. 6B). These
observations, together with the fact that the number of dots
increased in the course of infection, support the hypothesis
that the dot-like accumulation of virion proteins of three dif-
ferent compartments at the plasma membrane might corre-
spond to accumulating virion progeny. Nevertheless, it cannot
be excluded that at least a subset of these foci also represent
virions from the inoculum which did not successfully enter the
cell and thus remained bound to the plasma membrane.
In order to obtain a more detailed picture of the subnuclear
FIG. 7. High-resolution CLSM of large VP26 foci. (A) Vero cells were infected with rHSV-RY at an MOI of 0.3 PFU, fixed at the indicated
times postinfection, stained with DAPI, and observed by CLSM with settings specific for DAPI, EYFP (EYFP-gH fusion protein), and mRFP
(mRFP-VP26 fusion protein). Images represent single z stacks of the cells. (B) Panels a and c show magnifications of the mRFP-VP26 foci marked
with the numbered arrows shown in panel A, while panels b and d show surpass views of three-dimensional reconstructions of the same foci.
(C) Vero cells were infected with wt HSV-1 at an MOI of 10 PFU, fixed at 12 h p.i., and stained with the rabbit anti-VP26 PAb VP26/C and a
FITC-conjugated secondary antibody. HSV-1 DNA was detected by FISH using an Atto590-labeled probe. Cells were observed by CLSM with
settings specific for DAPI, FITC (VP26), and Atto590 (HSV-1 DNA). Images represent single z stacks of the cells.
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distribution of the large mRFP-VP26 foci, we infected cells
with rHSV-RY, fixed them at 16 or 20 h p.i., and stained the
nuclei with DAPI. CLSM analysis revealed that, at such late
time points, the large mRFP-VP26 foci were often located at
the very periphery of the nuclei (Fig. 7A) and that the density
of mRFP-VP26 within these large foci was not homogenous
(Fig. 7B). Rather, mRFP-VP26 accumulated strongly at the
rim and displayed only a weak accumulation in the interior,
suggesting a hollow structure of these foci (Fig. 7B). In addi-
tion, we observed that while some of the VP26 structures were
still separated from the nuclear membrane by a thin layer of
condensed chromatin (Fig. 7B, panels a and b), others dis-
placed the chromatin to such an extent that they virtually
gained access to the nuclear membrane, which was visible by
virtue of EYFP-gH fluorescence (Fig. 7B, panels c and d). In
order to test if these large VP26 foci corresponded to an
accumulation of DNA-filled capsids, we codetected VP26 and
HSV-1 DNA in wt HSV-1-infected cells (Fig. 7C). While VP26
and HSV-1 DNA colocalized within the RCs, the large VP26
foci did not contain HSV-1 DNA. Assuming that DNA within
virions is accessible for FISH, these data suggest that the large
VP26 foci do not correspond to accumulations of DNA-filled
capsids.
To ascertain that the distribution of the fluorescent virion
proteins corresponded to that of the respective wt proteins, we
performed infections with wt HSV-1 and detected VP16, gH,
and VP26 by immunofluorescence. CLSM analysis of stained
cells revealed that the patterns for all three wt virion proteins
were very similar to those observed with the recombinant vi-
ruses (Fig. 8A to C). However, it has to be noted that the
accumulation of VP16 in large foci at the nuclear periphery
and their colocalization with VP26 was not observed in wt
HSV-1-infected cells stained with VP26- and VP16-specific
antibodies (Fig. 8D). This analysis also demonstrated that the
structure of the large VP26 foci was identical to that observed
with the mRFP-VP26 fusion protein (Fig. 8C, panel h). Inter-
estingly, the proportion of cells displaying such large VP26 foci
appeared to be somewhat smaller in wt HSV-1-infected cells
than in cells infected with the recombinant viruses.
Time-lapse CLSM of cells infected with either rHSV-RYC
or rHSV-RY allowed us to obtain a dynamic view of the in-
teraction between VP16, gH, and VP26 in the infected cells
(Fig. 9; see also movies S1 to S3 in the supplemental material).
Specifically, the image series demonstrated a very dynamic
compartmentalization of VP16-ECFP in the course of infec-
tion. While VP16-ECFP initially steadily accumulated in the
nuclear RCs and later in the small foci in the periphery of the
RCs, there was a very rapid and pronounced recruitment of
VP16-ECFP out of the nucleus into the cytoplasm and, in some
cells, into the large mRFP-VP26 foci at the periphery of the
nucleus in a late stage of infection. This redistribution was
fairly rapid and generally occurred within 1 to 2 h (Fig. 9A). In
addition, the time-lapse series revealed the progressive accu-
mulation of EYFP-gH at the nuclear membrane and in the
perinuclear cytoplasmic pattern (Fig. 9A and B). Finally, the
analysis demonstrated that the initially small foci of mRFP-
VP26 expanded and coalesced to form much larger foci, which
were pushed toward the periphery of the nucleus as infection
progressed (Fig. 9A and B).
Ultrastructural analysis of rHSV-RYC-infected cells. Elec-
tron microscopy revealed clear indications for normal matura-
tion of the triple-fluorescent recombinant HSV-1, rHSV-RYC,
with identical phenotypes to wt HSV-1 (Fig. 10). These phe-
notypes include formation of capsids with occasional crystal-
line-like accumulation within the nucleus (Fig. 10C), budding
of capsids at the inner nuclear membrane (Fig. 10B), budding
of capsids at Golgi membranes (Fig. 10D), virions within
vacuoles (Fig. 10E), and virions in the extracellular space
(Fig. 10F).
DISCUSSION
Autofluorescent proteins have been used extensively to
study many different biological processes, including the repli-
cation cycle of viruses (reviewed in reference 5). Recombinant
herpesviruses encoding individual virus proteins fused with
autofluorescent proteins have previously been constructed to
study several different aspects of the herpesvirus life cycle,
including trafficking, assembly, and maturation (11, 13, 15, 17,
20, 35, 39). Here, we report for the first time the construction
and time-lapse analysis of a recombinant HSV-1 that simulta-
neously encodes virus proteins from three different virion com-
partments, capsid (VP26), tegument (VP16), and envelope
(gH), fused with different autofluorescent proteins (mRFP,
ECFP, and EYFP, respectively).
Crucial to the construction of the triple-fluorescent recom-
binant HSV-1 was the availability of a BAC-cloned HSV-1
genome (59), which facilitated the easy manipulation of the
virus genome in bacteria. The combination of the HSV-1 BAC
with the possibility for both positive and negative selection in
bacteria provided by the galK system (62) allowed the serial
introduction of the three fusion genes into the virus genome.
The reconstitution of recombinant virus progeny and the
elimination of the BAC backbone were accomplished fol-
lowing cotransfection of the recombinant HSV-1 BAC DNA
with a Cre recombinase-expressing plasmid in mammalian
cells (Fig. 1).
Western analysis of infected cells demonstrated that all
three fusion proteins were synthesized (Fig. 2). Interestingly,
the triple-fluorescent recombinant HSV-1, rHSV-RYC, was
replication competent, although with delayed kinetics, and in-
corporated all three fusion proteins into the different virion
compartments. It appeared that the fusion of EYFP to gH was
responsible for a delay in the kinetics of virus release (Fig. 3).
This is consistent with a previous report describing the fusion
of EYFP to the N terminus of gH (39). Although the authors
of that study contended that the recombinant virus replicated
to titers comparable to those of wt HSV-1, it has to be noted
that the wt virus used in their study (strain 17 syn) reached
only a titer of 5.25  106 PFU/ml, which is rather low for a wt
virus. The fusion of autofluorescent proteins to VP16 and
VP26 also seemed to affect virus titers, although there were no
indications that fusion to the essential VP16 would have a
greater impact on viral replication fitness than fusion to the
nonessential VP26. In addition, the analysis did not support
the notion that the effects of the individual fusions were addi-
tive. Rather it appeared that the addition of at least one
autofluorescent fusion protein to a virus protein resulted in a
somewhat delayed kinetics of virus production (gH) or reduced
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final titers (VP16 or VP26). Electron microscopy analysis re-
vealed that the triple-fluorescent recombinant HSV-1 was
comparable to wt HSV-1 also at the ultrastructural level (Fig.
10). Moreover, CLSM of infected cells demonstrated that the
distribution and compartmentalization of the three autofluo-
rescent fusion proteins encoded by rHSV-RYC were compa-
rable to those observed with either wt HSV-1 or recombinants
of HSV-1 that encode autofluorescent proteins fused with
FIG. 8. Immunofluorescence staining for VP16, gH, and VP26 in wt HSV-1-infected cells. (A) Immunofluorescence staining for VP16. Vero cells
were infected with wt HSV-1 at an MOI of 10 PFU. At the indicated times postinfection, the cells were fixed and stained with the anti-VP16 MAb LP1
and an AF594-conjugated secondary antibody, as well as DAPI. The cells were then observed by CLSM with settings specific for DAPI and AF594. Filled
arrowhead, VP16 foci in the periphery of RCs. (B) Immunofluorescence staining for gH. Vero cells were infected and stained as described for panel A,
except that the anti-gH MAb LP11 was used. (C) Immunofluorescence staining for VP26. Vero cells were infected and stained as described for panel
A, except that the rabbit anti-VP26 PAb VP26/C was used. Panel h shows a magnification of the VP26 focus marked with an arrow. (D) Vero cells were
infected as described for panel A, fixed at 16 h p.i., and stained with DAPI, the anti-VP16 MAb LP1 (detected with an AF594-conjugated secondary
antibody), and the rabbit anti-VP26 PAb VP26/C (detected with a FITC-conjugated secondary antibody). The cells were then observed by CLSM with
settings specific for DAPI, AF594 (VP16, shown in green), and FITC (VP26, shown in red). Images in panels A to D represent single z stacks of the cells.
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VP26, gH, or VP16 individually (Fig. 5 to 8) (13, 35, 39).
Finally, the strong dot-like association of autofluorescent fu-
sion proteins of three different virion compartments, VP16-
ECFP, mRFP-VP26, and EYFP-gH, at plasma membrane pro-
trusions (Fig. 6A and B) supports the hypothesis that these
dots indeed are mature virions and that progeny virions incor-
porate sufficient amounts of the fluorescent fusion proteins to
allow their visualization, although this has to be confirmed on
the ultrastructural level. Nevertheless, it would be less convinc-
ing to draw such a conclusion with a recombinant HSV-1 that
encodes only one or two autofluorescent virion proteins.
The major advantage of our approach is the possibility for
simultaneously visualizing the distributions and interactions
between different virus proteins and virion compartments on
the single cell level. Moreover, our strategy allows study of the
dynamics of these events in live cells. For example, mRFP-
VP26 and VP16-ECFP colocalized within RCs in the nucleus
but, in addition, they both also formed foci in the periphery of
the RCs that did not colocalize (Fig. 5). In a previous report it
was hypothesized that the VP16 foci in the periphery of the
RCs may correspond to sites where capsids acquire VP16 (35).
Our experiments, however, suggest that this hypothesis is un-
likely. In the course of the infection, the mRFP-VP26 foci
expanded and coalesced to form larger foci that relocated to
the periphery of the nucleus. In the majority of the cells,
VP16-ECFP was redistributed from the nucleus to the cyto-
plasm late in infection, in a process that occurred very rapidly
(generally within 1 to 2 h). Of note is that in a subset of cells,
VP16-ECFP was, in addition, recruited into the large mRFP-
VP26 foci at the periphery of the nucleus (Fig. 5 and 9; see also
movies S1 to S3 in the supplemental material). This phenom-
enon was, however, not observed in wt HSV-1-infected cells
stained with VP16- and VP26-specific antibodies, in which
VP26, but not VP16, was consistently observed in the large foci
at the nuclear periphery (Fig. 8). In contrast, the colocalization
of VP26 and VP16 in the cytoplasm late in infection was
readily observed in both rHSV-RYC- and wt HSV-1-infected
cells (Fig. 5 and 8). There are two possible explanations for this
discrepancy: first, the fusion of ECFP to VP16 may have al-
tered some of its biological properties, leading to its recruit-
ment into the large mRFP-VP26 foci at the nuclear periphery.
Second, it is conceivable that VP16 and VP26 similarly colo-
calized in wt HSV-1-infected cells but that the VP16-specific
antibody employed did not detect VP16 when present in the
FIG. 9. Time-lapse CLSM of rHSV-RYC- and rHSV-RY-infected cells. Vero cells were infected with rHSV-RYC (A) or rHSV-RY (B) at
MOIs of 2 and 0.3, respectively. Cells that just started to accumulate fluorescent proteins were monitored by CLSM with settings specific for ECFP
(VP16-ECFP), EYFP (EYFP-gH), and mRFP (mRFP-VP26). Selected frames at the indicated intervals are shown. Images were processed with
Imaris software in the surpass view mode. Arrowheads denote the cells described in the text.
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large VP26 foci at the periphery of the nucleus, possibly be-
cause of an altered conformation of VP16 in these structures.
However, the very late appearance of this colocalization (18 to
24 h p.i.) suggests that it likely does not represent a crucial step
in the assembly and egress of progeny virus, since infectious
progeny are produced already at earlier time points (i.e., 12 h
p.i.) (Fig. 3). The accumulation of VP26 in large nuclear foci
was previously documented in cells infected with wt HSV-1
FIG. 10. Electron micrographs of Vero cells infected with rHSV-RYC after prefixation at 24 h p.i. followed by freezing and freeze-substitution.
(A) Low-power micrograph showing Golgi membranes, virions within a vacuole (arrow), and capsids (arrowheads) within the cytoplasm and
budding at Golgi membranes, respectively. (B) Virion within the perinuclear space of the nuclear envelope. (C) Accumulation of capsids in a
crystalline manner within the nucleus. (D) Budding capsid at Golgi membranes. (E) Virion within a concentric vacuole. (F) Virions in the
extracellular space. Bars, 500 nm (A and C) and 100 nm (B, D, and E).
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and stained with VP26-specific antibodies, as well as by expres-
sion of VP26 fused to GFP. The formation of nuclear VP26
foci was demonstrated to depend on the presence of VP5 and
VP22a and to occur in an ATP-dependent manner (8, 11, 13,
52). These VP26 foci were hypothesized to correspond to the
sites of capsid assembly, similar to the assemblons described by
Ward and coworkers, which contained the capsid proteins
ICP35, VP5, and VP19c and formed very late in infection at
the periphery of the nuclear RCs (13, 61). Interestingly, Ward
et al. (61) detected a partial colocalization between assemblons
and VP16 by staining with VP19c- and VP16-specific antibod-
ies. However, this partial colocalization clearly differs from the
almost perfect colocalization of VP16-ECFP and mRFP-VP26
in large foci at the nuclear periphery observed in our study
(Fig. 5). The ultrastructural correlate of this colocalization
remains to be determined. It is possible that the VP26 foci at
the nuclear periphery may represent the accumulation of dead-
end products, as previously suggested for assemblons (10, 36),
to which VP16 is recruited late in infection. This hypothesis is
further supported by the finding that these structures do not
contain HSV-1 DNA, indicating that they do not correspond to
accumulations of DNA-filled capsids (Fig. 7).
In summary, this study demonstrates the feasibility of the
construction of a recombinant HSV-1 simultaneously express-
ing autofluorescent proteins fused to VP16, VP26, and gH.
This study sheds light on the spatial and temporal organization
of HSV-1 infection at the single-cell level. Specifically, the
simultaneous fluorescence labeling of several virion compo-
nents allowed assessment of the interactions of the different
viral proteins in the course of the infection. This approach may
be used to address several open questions in HSV-1 biology,
for example, the spatial organization of capsid assembly and
maturation by fluorescent labeling of several components of
the pro-capsid and those of mature capsids. In addition, fluo-
rescently labeled virus proteins may be combined with systems
for the live visualization of viral DNA, as previously described
for several viruses, such as HSV-1, Epstein-Barr virus, and
adeno-associated virus (1, 23, 28, 29, 58), to specifically assess
the dynamics of the association of viral proteins with viral
DNA. Finally, the simultaneous fluorescent labeling of capsid,
tegument, and envelope components may prove useful for the
study of virus trafficking, for example, to assess and compare
the composition of virions transported in an anterograde ver-
sus retrograde direction within axons (2–4, 20, 40).
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Abstract: Herpes simplex virus type 1 (HSV-1) amplicons can accommodate foreign DNA of any size up to 150 kbp and, 
therefore, allow extensive combinations of genetic elements. Genomic sequences as well as cDNA, large transcriptional 
regulatory sequences for cell type-specific expression, multiple transgenes, and genetic elements from other viruses to 
create hybrid vectors may be inserted in a modular fashion. Hybrid amplicons use genetic elements from HSV-1 that 
allow replication and packaging of the vector DNA into HSV-1 virions, and genetic elements from other viruses that 
either direct integration of transgene sequences into the host genome or allow episomal maintenance of the vector. Thus, 
the advantages of the HSV-1 amplicon system, including large transgene capacity, broad host range, strong nuclear 
localization, and availability of helper virus-free packaging systems are retained and combined with those of heterologous 
viral elements that confer genetic stability to the vector DNA. Adeno-associated virus (AAV) has the unique capability of 
integrating its genome into a specific site, designated AAVS1, on human chromosome 19. The AAV rep gene and the 
inverted terminal repeats (ITRs) that flank the AAV genome are sufficient for this process. HSV-1 amplicons have thus 
been designed that contain the rep gene and a transgene cassette flanked by AAV ITRs. These HSV/AAV hybrid vectors 
direct site-specific integration of transgene sequences into AAVS1 and support long-term transgene expression. 
Keywords: HSV-1 amplicon vectors, adeno-associated virus, herpes simplex virus type 1, hybrid vectors. 
HERPES SIMPLEX VIRUS TYPE 1 - BIOLOGICAL 
PROPERTIES 
 Herpes simplex virus type 1 (HSV-1) is a member of the 
family Herpesviridae, subfamily Alphaherpesvirinae, genus 
Simplexvirus. It is a common human pathogen that causes 
infections of the orofacial mucosal surfaces and may rarely 
cause acute hepatitis, kerato-conjunctivitis or meningo-
encephalitis. 
 The HSV-1 particle is composed of three different 
compartments, capsid, tegument, and envelope. The capsid 
proteins are involved in the formation and maturation of the 
icosahedral capsid [1]  and packaging of the viral genome [2-
6]. The tegument, which is located between capsid and 
envelope, is composed of viral proteins involved in transport 
of capsids to nuclear pores, attachment to the nuclear pore 
complex [7], release of the virus genome from the capsid 
into the nucleus [8], and remodeling the host cell 
environment to optimize replication [9-14]. The viral 
envelope is a lipid bilayer of host origin that contains 11 
viral glycoproteins. These play important roles in viral 
attachment, entry, cell to cell spread, and egress [15, 16]. 
HSV-1 can enter the cells by receptor-mediated fusion 
between virus and cell membrane [17-20]. However, 
depending on the cell type and virus strain, HSV-1 can 
penetrate the host cell also by endocytosis [20-22]  and 
phagocytosis [23]. In the cytoplasm, the capsid is transported 
to the nucleus via interactions with the minus-end-directed 
microtubule motor protein dynein [24-26]  Capsids bind to 
the nuclear pore complex and release the DNA genome into 
the nucleus [7, 27, 28]. 
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 The HSV-1 genome is a double-stranded DNA (dsDNA) 
of 152 kbp. It is organized in two segments, unique long 
(UL) and unique short (US), both of which are flanked by 
inverted repeats (see Fig. 1). The essential cis elements for 
viral DNA replication and encapsidation include the origins 
of DNA replication, located in the UL (oriL) and TRs, (oriS) 
regions [29, 30], and the packaging/cleavage signals (pac) 
that reside in the a sequences located at both termini of the 
genome as well as at the junction between the long and the 
short segments [31]. The viral genome circularizes after it 
reaches the nucleus [32] and serves as a template for DNA 
replication. However, there is also evidence that 
circularization is not required for replication [33]. The 
majority of the replicative intermediates are long 
concatemers that are thought to have been synthesized by a 
rolling-circle mechanism [34-36]. The concatemers are 
cleaved into unit-length genomes at the pac signals after 
filling pre-formed capsids [36, 37]. 
 HSV-1 encodes approximately 89 genes [38], which are 
expressed in a cascade of three temporal phases: immediate-
early, early, and late. The late genes can be subdivided in 
leaky-late (expression is not dependent on viral DNA 
synthesis) and true-late (expression depends on viral DNA 
synthesis) [31, 39, 40]. 
 There are several hypotheses on the mechanisms of 
envelopment of the nucleocapsid. The generally accepted 
view suggests a two-step envelopment process in which the 
capsid acquires a primary envelope by budding at the inner 
nuclear membrane and then is de-enveloped by fusion with 
the outer nuclear membrane [41, 42]. The secondary 
envelope is acquired when the capsid buds into the Golgi or 
cytoplasmic vesicles [43-49]. The alternative pathways 
described include (i) budding at the inner nuclear membrane 
followed by intraluminal transport via ER and Golgi and (ii) 
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exit via impaired nuclear pores and envelopment at the outer 
nuclear membrane or ER membrane [50-52]. Regardless of 
the mechanism of envelopment, mature virions seem to exit 
the cell by exocytosis via intraluminal transport to Golgi 
cisternae and formation of transport vacuoles [53-55]. 
An important aspect of HSV-1 biology is the capability of 
this virus to establish latent infections in sensory neurons of 
the trigeminal ganglia [56]. The latent HSV-1 genome is a 
circular, condensed episome, and viral gene expression is 
limited to the non-coding, latency-associated transcripts 
(LATs) [57]. Expression of LATs was demonstrated to 
increase the number of neurons in which latency is 
established [58] and to affect the efficiency of reactivation 
[59, 60]. Recent findings that LAT encodes several micro 
RNAs (miRNA) in HSV-1 infected cells corroborates with 
the proposed hypothesis that the exonic regions of LAT 
might function as primary miRNA precursors [61]. At least 
two of the identified miRNA precursors in latently infected 
neurons may facilitate the establishment and maintenance of 
viral latency by post-transcriptionally regulating viral gene 
expression [62-65]. 
 Latent HSV-1 can periodically reactivate in response to a 
variety of stimuli, including fever, UV light, hormonal 
imbalance, malignancy or immune suppression, and enter a 
new lytic cycle, usually at the site of the primary infection. 
Recently, the requirement of ICP0 for viral DNA replication 
[66-68]  and for exit from latency has been reconsidered, as 
in vivo studies showed that reactivation of HSV-1 genomes 
does not depend on viral DNA amplification [69]  nor 
functional ICP0 [70]. Upon stress conditions, and in the 
absence of other viral proteins, VP16 was demonstrated to be 
activated [71], supporting the hypothesis that de novo 
expression of VP16 regulates entry into the lytic program in 
neurons. Repeated reactivation does not appear to kill the 
neurons, indicating that the extent of virus replication must 
be limited. 
 The understanding of the biological properties of HSV-1 
and the molecular mechanisms of virus replication have 
allowed the design of specialized vector systems for somatic 
gene therapy, oncolytic virotherapy, and vaccination. 
HSV-1 BASED VECTOR SYSTEMS 
 HSV-1 is an attractive vector for gene therapy due to its 
(i) large transgene capacity, (ii) high transduction efficiency 
and broad cell tropism that includes both dividing and non-
dividing cells, and (iii) ability to establish latency while 
maintaining at least some transcriptional activity. However, 
as HSV-1 is a human pathogen, its use as a vector can result 
in host immune responses and cytopathogenic effects in 
patients, and possibly reactivation of and recombination with 
latent wild-type HSV-1. Taking these aspects into 
consideration, two different HSV-1-based vector systems, 
recombinant and amplicon, have been developed. 
 Initially, recombinant herpesviruses were constructed for 
functional studies of viral genes and development of 
vaccines. However, advances in site-specific modification of 
the viral genome facilitated the use of HSV-1 as a gene 
transfer vehicle [72]. Different approaches for the 
construction of recombinant HSV-1 vectors are based on the 
target tissue and purpose of gene delivery e.g. replication-
conditional recombinant HSV-1 vectors are suitable for 
therapeutic treatment of tumors; replication-defective 
recombinant HSV-1 vectors are applied for gene replacement 
therapy [73]. Although some preclinical studies show 
promising results, several obstacles have to be overcome: (i) 
replication-defective mutants of HSV-1 can cause cytopathic 
effects in primary cultures of neuronal cells and 
inflammatory responses in neural tissue in vivo; (ii) most 
viral and nonviral promoters are silenced after injection into 
the brain. Therefore, the main focus in the development of 
new HSV-1-based vectors has been directed at achieving 
nontoxic, long-term gene expression in neurons. 
 The second type of HSV-1-based vector system, the 
HSV-1 amplicon vector, originated about three decades ago. 
Spaete and Frenkel analyzed the nature of defective virus 
genomes generated during the passage of standard HSV-1 
stocks at high multiplicity of infection [74, 75]. Their 
investigations revealed that an ori and a pac signal were the 
only two cis-acting sequences required for the replication 
and packaging of defective virus genomes in the presence of 
trans-acting HSV-1 helpervirus (Fig. 2A). The word 
amplicon was used to delineate the fact that multiple copies 
of a DNA sequence of interest can be amplified in a head-to-
tail arrangement in concatemeric defective virus genomes 
and packaged into HSV virions [76]. HSV-1 amplicon 
vectors share similar structural and immunological properties 
with the wild type HSV-1 particle, which can trigger cell 
signaling and cellular responses that may have a transient 
impact on cell homeostasis or gene expression. However, the 
lack of virus genes and protein synthesis reduces the risk of 
reactivation, complementation and recombination with latent 
or resident HSV-1 genomes. 
 HSV-1 amplicon vectors have been used to infect 
efficiently a number of different cell types, including 
 
Fig. (1). Schematic representation of the HSV-1 genome. The HSV-1 genome is a linear double stranded DNA of approximately 152 kb in 
size, composed of two unique segments, UL and US, which are flanked by inverted repeats, TRL /IRL and IRS/TRS. The minimal cis elements 
required for HSV-1 DNA replication and packaging include the origin of DNA replication, ori, and the cleavage/packaging, pac, signals. 
oriL oriSoriSpac pacpac
UL IRL USIRSTRL TRS
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epidermal cells and dendritic cells in the skin [77, 78], some 
cell types in the cochlea [79, 80], hepatocytes [81], skeletal 
muscle [82], neurons [83], glioblastoma, and other tumor 
cells [84-86]. Despite the promising features of the HSV-1 
amplicon vector as a gene delivery system, further 
developments concerning vector production, stability of 
transgene expression, and interaction with target cells are 
essential. Recently, the presence of bacterial sequences in the 
amplicon genome was shown to be responsible for the 
formation of inactive chromatin, leading to a rapid transgene 
silencing [87]. Strategies to increase the stability of 
transgene expression included the use of: (i) cell type-
specific promoters [88, 89]  and (ii) genetic elements from 
other viruses that confer genetic stability, such as integration 
of the transgene into host chromosomes [90, 91]  or 
conversion of the amplicon genome into a replication-
competent extrachromosomal element [92-95]. 
 One of these strategies, the combination of genetic 
elements from HSV-1 amplicons and adeno-associated virus 
(AAV) to achieve site-specific integration of the transgene 
into the host genome and long-term transgene expression is 
described in detail below, after a short introduction into 
AAV biology. 
ADENO-ASSOCIATED VIRUS – BIOLOGICAL PROP- 
ERTIES 
 Adeno-associated virus (AAV) belongs to the genus 
Dependovirus within the subfamily Parvovirinae, family 
Parvoviridae [96]. Different AAV serotypes have been 
identified that can infect a broad range of species; about 11 
serotypes and more than 100 variants of AAV infect 
primates. Based on serological studies, AAV serotypes 2, 3, 
and 5 most probably have a human origin [97, 98], while 
AAV4 appears to have originated in monkeys [99]. AAV6 
shares some genomic similarities with AAV2 and AAV1, 
raising the hypothesis that a recombination event could have 
occurred in vivo or in cell culture [100, 101]. The AAV 
serotypes 1 to 6 were isolated as contaminants in laboratory 
adenovirus stocks, while AAV 7, 8, 9, 10, and 11 were 
isolated as DNA molecules using a “signature PCR”, a 
 
Fig. (2). Viral vectors. A) HSV-1 amplicon. The HSV-1 amplicon contains three types of genetic elements: i) sequences from bacteria 
(colE1 and ampR) that allow plasmid propagation in E. coli; ii) sequences from HSV-1, in particular an origin of DNA replication (ori) and a 
DNA packaging/cleavage signal (pac), which allow replication and packaging of the amplicon DNA into HSV-1 particles in the presence of 
HSV-1 helper functions in mammalian cells; and iii) a transgene cassette with the gene of interest. B) Recombinant AAV vector. 
Recombinant AAV vectors are bacterial plasmids that contain the AAV ITRs flanking a transgene of interest. Replication of the ITR cassette 
and packaging into AAV particles is achieved by supplying helpervirus functions and the rep and cap genes in cis or trans but outside the 
ITR cassette. C) HSV/AAV hybrid amplicon. In addition to the HSV-1 amplicon elements, HSV/AAV hybrid amplicon vectors contain the 
AAV rep gene and a transgene of interest flanked by AAV ITRs. D) HSV/EBV hybrid amplicon. In addition to the HSV-1 amplicon 
elements, HSV/EBV hybrid amplicon vectors contain the EBV origin of DNA replication (oriP) and the gene encoding EBNA-1 which 
together can support episomal retention and segregation of the vector in dividing cells. E) HSV/RV hybrid amplicon. In addition to the 
HSV-1 amplicon elements, HSV/RV hybrid amplicon vectors contain the retrovirus (MoMLV) gag, pol, and env genes, and the RV LTRs 
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screening-based strategy [102]. Despite being widespread 
among species and infecting different tissues, AAV 
infections have not been associated with any pathology. 
Primate AAV serotypes share significant sequence 
similarities, and the occurrence of cross-reaction of 
neutralizing antibodies may be species specific or depend on 
tissue type or route of administration [101, 103, 104]. 
 The genome of AAV is a linear single stranded DNA of 
4.7 kb, and either the positive or negative strand can be 
packaged with equal efficiency. The genome is flanked by 
inverted terminal repeats (ITR) of 145 bp, containing a 
palindromic sequence that forms a hairpin as a T-shaped 
secondary structure. The Rep binding site (RBS) and the 
terminal resolution site (TRS) are regions within the ITRs 
that play important roles in the replication and packaging of 
the AAV genome [105]  (Fig. 3A). Two open reading frames 
(ORFs), Rep and Cap, are responsible for encoding 
overlapping proteins through alternative splicing (Fig. 3B). 
The Rep proteins, Rep78/68, and Rep52/40 are transcribed 
from two different promoters, p5 and p19, respectively, and 
are involved in DNA replication, transcription, and 
chromosomal integration. The p5 promoter contains a TATA 
box, a RBS, a TRS, the Yin Yang 1 (YY1) binding site, and 
a downstream sequence that can form a hairpin structure. 
The RBS is involved in Rep-mediated promoter regulation 
activity [106, 107], thus in the absence of helper functions 
small amounts of Rep are expressed that bind to the p5 
promoter inhibiting transcription [108, 109]. The regulatory 
activity of Rep seems to be involved in the maintenance of a 
constant ratio of Rep and Cap proteins during infection in 
order to keep the balance between AAV genome replication 
and packaging. The Cap ORF encodes three overlapping 
proteins, VP1, VP2 and VP3, from a single promoter, p40. 
These structural proteins compose the AAV icosahedral 
capsid whose diameter ranges from 18 to 26 nm [110]. 
 
Fig. (3). Schematic map of the wild type AAV genome. A) 
Secondary structure formed by the inverted terminal repeat, ITR. 
Depicted are the Rep binding sites, RBEs, and the terminal 
resolution site, TRS. B) The AAV genome expresses two clusters 
of genes, rep and cap, from three different promoters, p5, p19, p40, 
by alternative splicing. 
 The replication of the AAV genome is based on a 
“rolling hairpin model”. The hairpin structure at the ITR acts 
as a primer that converts the DNA into a double-stranded 
template, and together with the essential cis-acting elements 
RBS and TRS, and helpervirus functions, the replication and 
transcription of the AAV genome is initiated [111-113]. The 
Rep78/68 proteins play major roles in the replication process 
due to DNA-binding, endonuclease, and helicase activities. 
After binding to the RBS, Rep induces a site- and strand-
specific nick at the TRS, creating a new genome end 
allowing the reinitiation of the synthesis and formation of a 
monomer extended form that can be packaged [114]. If the 
hairpin structure in the monomer turnaround form is not 
resolved before reinitiation on the other genome end, 
continued synthesis leads to double stranded dimer 
molecules, in which two genomes in the inverted 
orientations (head-to-head or tail-to-tail) are covalently 
joined by a single ITR [115]. Interestingly, the RBS and TRS 
signals located within the p5 promoter sequence have been 
demonstrated to act together as an alternative origin of DNA 
replication in the presence of adenovirus [116, 117]  or 
HSV-1 helpervirus functions [108]. Replication from a 
plasmid cloned p5 replication origin led to the accumulation 
of large, head-to-tail linked concatameric replication 
products, which could readily be packaged into HSV-1 
virions if the HSV-1 packaging/cleavage signal was included 
on the plasmid [108]. These findings indicate that the AAV 
p5 replication origin could substitute for the HSV-1 origin of 
DNA replication on HSV/AAV hybrid vectors (see below). 
AAV is a replication defective virus as it depends on a 
helper virus, such as adenoviruses [118], a herpesvirus [119-
121], or vaccinia virus [122]  for productive replication (Fig. 
4). Helper viruses are also responsible for inducing a cell 
cycle arrest in late S or G2 phase, as in the case of 
adenoviruses [123]  or for down regulating host cell 
functions as in the case of HSV-1 as the helpervirus [124, 
125]. 
 Many studies have assessed the different elements from 
the helperviruses required for AAV replication. A model has 
been proposed where the HSV-1 helicase/primase proteins 
constitute a scaffold that recruits ICP8, Rep and cellular 
replication (RPA) proteins to the self-primed AAV DNA 
into replication compartments [126-129]. The HSV-1 
polymerase complex is preferentially used for AAV 
replication instead of the cellular machinery [113, 130]. 
Interestingly, an inhibitory effect of Rep78/68 proteins has 
been described on HSV-1 replication [131, 132], suggesting 
a regulatory effect of AAV over HSV-1, thereby limiting 
expression of HSV-1 early genes [113, 129]. 
 In the absence of helpervirus, the AAV genome can 
integrate into a specific site termed AAVS1, on chromosome 
19q13.3-qter of human cells [133-136]  (Fig. 4). The 
integration is mediated by Rep78/68 and ITRs through a 
nonhomologous deletion/insertion recombination event [134, 
136-143]. Also, an integration efficiency element (IEE) has 
been identified within the p5 promoter of AAV [144], and 
more specifically a 16-bp RBE was shown to be sufficient 
for AAV genome integration [145]. Rescue of the integrated 
AAV genome is possible by superinfection with helper virus 
[130]. Although HSV-1 ICP0 seems to contribute to the 
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Fig. (4). The life cycle of AAV. Co-infection of AAV and 
helpervirus, adenovirus or HSV-1, leads to viral gene expression, 
viral DNA replication, and production of progeny virus. In the 
absence of helpervirus, the genome of AAV can integrate into a 
specific site on human chromosome 19. In the presence of 
helpervirus, integrated AAV genomes are rescued and enter the 
lytic replication cycle. 
it is not sufficient to induce rep synthesis [130]. Some 
studies have demonstrated the autonomous replication of 
AAV under special conditions [147-149], however, the 
efficiency of replication is significantly lower than in 
presence of helpervirus functions. 
 AAV can infect different tissues and bind to unique 
cellular receptors, which can account for a serotype-specific 
tissue tropism. Several cellular receptors used by AAV for 
cell entry have been identified, including heparan sulfate 
[150], fibroblast growth factor receptor [151], and integrin 
alphaVbeta5 [152]. The initial steps of AAV infection, 
attachment to cellular glycosaminoglycan receptors and 
interactions with coreceptors seem to define the intracellular 
trafficking pathway of the capsid. Upon entry, AAV capsids 
are endocytosed via clathrin-coated pits [153], a process that 
requires dynamitin [154], and transported through both late 
and recycling endosomes. Trafficking in recycling 
endosomes appears to be favorable for efficient transgene 
expression [155]. The process of uncoating is still not well 
characterized [153, 156], however, AAV appears to enter the 
nucleus through a mechanism independent of the nuclear 
pore complex [157]. 
AAV BASED VECTORS 
 The broad cell tropism, lack of pathogenicity, and stable 
long-term gene expression make AAV an attractive vector 
for gene therapy [158]. AAV2 was the first AAV isolate to 
be developed into a recombinant vector for transgene 
delivery as it has been shown to infect a broad range of cell 
types in animal models [159], showing high efficiency in 
most of the tumor cells tested [160]. Recombinant AAV 
vectors are constructed by replacing the Rep and Cap ORFs 
with a transgene of interest flanked by the ITRs. Rep, Cap 
and helper functions can be supplied in trans in order to 
allow replication of the transgene in the host cell [135]  (Fig. 
2B). Different methods of delivering helper functions have 
evolved, from co-infection with Ad or HSV-1 [161, 162], to 
plasmid-based protocols [163], and stable-expression by cell 
lines [164-166]. The development of a baculovirus based 
vector production method in insect (SF9) cells has also 
shown promising results [167, 168]. 
 Recombinant AAV vectors have been tested in 
preclinical studies for a variety of diseases such as 
hemophilia, -1 anti-trypsin deficiency, cystic fibrosis, 
Duchenne muscular dystrophy, rheumatoid arthritis, prostate 
and melanoma cancer, Canavan disease [169], Alzheimer’s, 
and Parkinson’s [170]. 
 Recombinant AAV have shown efficient transduction of 
different regions of the brain, and are currently used in several 
clinical trials for neurological disorders [171-173]. Increased 
interest in designing AAV vectors for the treatment of 
neurodegenerative diseases that require gene delivery to broad 
areas or very local and specific areas of the brain are now the 
focus of many studies [174]. AAV2 has been the most widely 
used AAV serotype for gene delivery to the CNS, transducing 
almost exclusively neurons in different brain structures [175-
178], and supporting long-term transgene expression in the CNS 
[179-181]  as well as in the dorsal root ganglia [182]. AAV2 has 
shown higher transduction efficiency in glioblastoma in vitro 
and in vivo when compared to serotypes 4 and 5 [183]. 
However, other studies have demonstrated a higher distribution 
and transduction in the CNS when using rAAV serotypes 1 and 
5 [175, 184, 185]. The different AAV serotypes have been 
exploited on their ability to efficiently transduce distinct regions 
of the brain due to different cellular tropisms [174, 183, 186]. 
Immune Response to rAAV Vectors 
 The brain has been thought to be an immune privileged, 
compartmentalized organ that lacks an adaptive immune 
response. Some studies have suggested that viral vectors 
induce little immunogenicity, especially when injected once 
in the parenchyma of naïve animals [104, 187, 188], or that 
the presence of antibodies to both capsid proteins and 
transgene products seems not to correlate with reduction in 
transgene expression [187, 188]. Further studies with pre-
immunized animals, however, established that circulating 
neutralizing antibodies can affect intracerebral rAAV-
mediated transduction, and even suggested that the adaptive 
arm of the immune system can be primed by intracerebral 
rAAV2 administration [104]. 
 Immune responses in the absence of expression of AAV 
genes have also been observed in naïve animals in a dose-
dependent manner [104]. This has been suggested to occur 
due to the slow process of AAV capsid uncoating, thus 
allowing antigen presentation of processed capsid peptides 
by MHC-I, or by an immune reaction specific to the 
transgene [189, 190]. 
Improvements on rAAV Vectors 
 Despite the explicit advantages of rAAV as a vector for 
gene therapy, improvements in the regulation of transgene 
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Much research is focused on efforts to limit vector spread, in 
order to achieve specific tissue or organ delivery, or to 
enable the transduction of tissues that are refractory to 
naturally occurring AAV vectors. Engineering of AAV 
vectors for altered tropism, enhanced transduction efficiency, 
and evasion of antibody neutralization includes manipulation 
of the AAV capsid by insertion of peptide ligands, 
conjugate-based targeting, and presentation of large protein 
ligands on the AAV capsid [191]. The diversity of AAV 
serotypes brings the possibility to evade preexisting 
immunity by engineering hybrid or pseudotyped AAV 
vectors derived from different serotypes [192-194]. 
 Another strategy that focuses on the transduction 
efficiency is the improvement on the second-strand synthesis 
step during AAV replication (Fig. 5). The development of 
self-complementary AAV (scAAV) vectors relies on the 
packaging of an inverted repeat genome that can fold into 
dsDNA without the requirement for DNA synthesis or base-
pairing between multiple vector genomes, thereby bypassing 
the rate-limiting second-strand DNA synthesis [195]. The 
scAAV vectors displayed enhanced transduction in 
comparison with conventional AAV vectors in some tissues 
and cancer cells but their efficiency still depends on tissue, 
cell type, and route of administration [196, 197]. 
 
Fig. (5). Comparison between self-complementary AAV 
(scAAV) and rAAV vectors. scAAV delivers a dimeric inverted 
repeated DNA molecule thereby bypassing the rate-limiting second-
strand DNA synthesis of rAAV. 
 Modifications on purification protocols using 
chromatography techniques have also contributed to 
increased yields of rAAV and to considerable elimination of 
contaminating infectious helper viruses [198-201]. 
 
HSV/AAV HYBRID VECTORS 
Rationale on the Construction of Hybrid Vectors 
 Hybrid gene transfer vectors are designed to combine 
advantageous properties of different viruses to enhance 
efficiency of transgene delivery, vector stability and long-
term transgene expression, while maintaining high safety 
standards [133, 202]. For example, the instability of HSV-1 
amplicon vector delivered transgene DNA and transient 
transgene expression can be overcome by introducing 
genetic elements that allow the amplicon DNA to be 
maintained as an episome or to integrate into the host cell 
genome [203]. The maintenance of the DNA as a replicating 
episome with chromosome-segregating capability can be 
achieved by using oriP and the EBNA-1 gene from Epstein-
Barr virus (EBV) [204]. Alternatively, viral elements such as 
AAV ITR and rep [91, 178], or retrovirus components [205]  
can be used to allow HSV-1 amplicon vector delivered 
transgenes to integrate into the cell genome. HSV-1 based 
hybrid vectors have also been constructed to facilitate the 
production of rAAV vectors. 
Hybrid Vectors for the Production of rAAV Vectors 
 The efficiency of rAAV production for routine clinical 
use is a major concern, as most of the systems used for 
rAAV production rely on transfection protocols, thereby 
limiting scale-up procedures [206-209]. Replication 
defective rHSV-1 vectors lacking specific genes (e.g. ICP4, 
ICP27), which have been developed in order to reduce 
pathogenicity and cytotoxic effects in vector infected cells, 
can also be used as helper viruses for the production of 
rAAV vectors. Specifically, the ability of rHSV-1 that lack 
the ICP27 gene to efficiently act as a helper virus for rAAV 
production has been demonstrated [210] ; rAAV production 
in the absence of ICP27 appeared to be even enhanced. This 
may be due to the role of ICP27 in regulating transcription 
and translation of viral and cellular genes, for instance in the 
inhibition of splicing of host and AAV transcripts, which 
reduces synthesis of Rep and Cap proteins. The use of 
replication defective rHSV-1 to deliver AAV rep and cap 
has also been explored and is a very promising approach as it 
generates higher yields of rAAV with no detectable 
helpervirus contamination. Moreover, when allied to 
infection of a cell line that provides the rAAV template to be 
packaged, transfection steps can be avoided entirely for the 
production of rAAV [161, 211]. A protocol with a single 
infection step can also be accomplished by inserting an AAV 
ITR-flanked transgene (rAAV genome) cassette into the 
genome of the rHSV-1 helpervirus [210]. 
HSV/AAV Hybrid Vectors for Site-Specific Integration 
into AAVS1 
 Over the past 2 decades, the development of improved 
HSV-1 amplicon packaging systems, in particular the 
development of helper virus-free packaging systems, has 
greatly reduced toxicity and immunogenicity, but has had 
little effect on the stability of amplicon-mediated transgene 
expression [81, 212-214]. On the other hand, classical rAAV 
vectors have a small transgene capacity (~4.6 kb) and, due to 
the replacement of the rep and cap genes by transgenic 
sequences, do not conserve the potential of the parent virus 





HSV/AAV Hybrid Vectors The Open Virology Journal, 2010, Volume 4    115 
 HSV/AAV hybrid amplicon vectors have been developed 
to overcome these limitations. In addition to the standard 
HSV-1 amplicon elements, HSV/AAV hybrid vectors 
incorporate the AAV rep gene and a transgene cassette that 
is flanked by AAV ITRs (Fig. 2C). By placing the rep gene 
outside of the ITR cassette, it is not expected to integrate into 
the host genome. Loss of rep after integration of the ITR 
cassette eliminates a potential source of toxicity and the risk 
of rescue/excision of integrated ITR cassettes if the cell is 
infected by a helpervirus. Because HSV/AAV hybrid vectors 
can be packaged into HSV-1 virions, they conserve the high 
efficiency of gene transfer, the large transgene capacity, and 
the availability of helper virus-free packaging systems. 
However, after delivery into the host cell nucleus, the vector 
has the potential to act like AAV with rep-mediated site-
specific integration of the ITR-flanked transgene cassette 
into the AAVS1 sequence of human chromosome 19 [91]. 
 The initial study on HSV/AAV hybrid vectors 
demonstrated that these vectors can be packaged into HSV-1 
virions by using either helper virus-dependent or helper 
virus-free packaging systems [81, 215]. Hybrid vectors 
supported transgene retention and expression significantly 
longer than standard amplicons [215]. Although the 
possibility of transgene integration had not been specifically 
addressed in that study, the percentage of cells expressing 
the transgene was consistently higher with hybrid vectors 
that contained the rep gene than with those without rep, or 
with standard amplicons. 
 Two other studies have specifically addressed the 
question whether HSV/AAV hybrid vectors mediate 
genomic integration, both randomly or site-specifically at the 
AAVS1 site on human chromosome 19 [91, 178]. Heister 
and colleagues constructed HSV/AAV hybrid vectors that 
contained enhanced green fluorescent protein (EGFP) 
reporter gene flanked by the AAV ITRs and AAV rep. 
Replication assays demonstrated that both the AAV elements 
and the HSV-1 elements were functional in the context of the 
hybrid vector, as shown by the presence of replication 
intermediates of the ITR-flanked transgene cassette and high 
molecular-weight concatemeric products of replication from 
the HSV-1 origin of DNA replication. Such hybrid vectors 
could be packaged into HSV-1 virions, although the rep 
sequences incurred a drastic (20 to 2,000-fold) reduction in 
titers. Site-specific integration at AAVS1 was directly 
demonstrated by PCR and sequence analysis of ITR-AAVS1 
junctions in transduced human 293 cells. The junctions were 
similar to those that had been identified in cells infected with 
wt AAV [133, 134, 138, 139, 216-218]. Similar results were 
obtained by Wang and colleagues who have used also 293 
cells and extended the study to other cell lines, including 
glioma cells (gli36) and primary myoblasts [178]. These 
investigators used HSV/AAV hybrid vectors that contained 
rep68 and rep78, or no rep, and an ITR-flanked transgene 
cassette that consisted of an EGFP reporter gene and a 
neomycin resistance gene. In order to overcome the low-titer 
packaging problem inherent to the rep gene, they worked on 
position/orientation effects and found that a decent amplicon 
vector titer is achieved when the rep genes are placed 
downstream of the ITR cassette in the forward orientation. 
Rep mediated a significantly improved efficiency of stable 
tranduction in all human cells tested, including 293 cells, 
glioma cells and primary myoblasts. Although neomycin 
selection was employed for cell cloning, a high proportion of 
the stably transduced cells had the transgene sequences 
correctly integrated at the AAVS1 site. In summary, 
inserting the AAV ITRs and rep genes into an HSV-1 
amplicon considerably improved the frequency of stable 
transgene expression in various proliferating human cell 
types. Integration events of 4-5 kb ITR-flanked transgene 
cassettes occurred at a rate of approximately 10-30 % of the 
HSV/AAV hybrid vector infected cells, and about 50% of 
those events occurred specifically at the AAVS1 locus [91, 
178]. The potential for AAVS1-specific integration and 
expression of an entire gene under control of its endogenous 
promoter using the HSV/AAV vector has also been 
evaluated. Large functional inserts (approximately 100 kb) 
could be integrated at the AAVS1 site but with a reduced 
efficiency [219, 220]. 
 While the expression of rep78/68 has been demonstrated 
to be essential for the ability of HSV/AAV hybrid vectors to 
mediate site-specific integration, Rep proteins have a strong 
inhibitory effect on the HSV-1 replication machinery [91, 
132, 178, 221]. As a consequence, the titers of HSV/AAV 
hybrid vectors are up to 2000-fold lower than those of 
standard amplicon vectors [91]. This could be due to (i) the 
toxicity of Rep, resulting in compromised cell metabolism 
[222], (ii) the ability of Rep to inhibit HSV-1 replication 
[131, 132], or (iii) the excision of ITR-flanked sequences 
from the amplicon DNA during packaging. 
 Potential improvements of the HSV/AAV amplicon 
vectors may rely on the appropriate use of the p5 promoter 
sequence. Indeed, the p5 promoter driving the expression of 
rep78/68 in the afore described HSV/AAV hybrid vectors 
[91, 178]  may promote vector-backbone integration [144, 
223]  owing to its location outside of the therapeutic 
transgene cassette. In addition, it may also interfere with 
site-specific integration of the p5-free ITR-flanked 
transgenes. Transferring the p5 promoter sequence from the 
rep expression cassette to the transgene cassette may not 
only solve the problem of inadvertent integration of vector 
backbone sequences but also increase the efficiency of site-
specific integration of the ITR cassette [144, 223]. 
 Liu et al. developed a strategy to overcome the negative 
effect of AAV Rep on hybrid vector replication and 
packaging [224]. These investigators designed an HSV/AAV 
hybrid vector in such a way that little or no rep was 
expressed during packaging. However, rep was expressed in 
transduced cells if Cre-recombinase was provided; following 
site-specific integration, rep was suppressed again. These 
vectors mediated stable expression in 22% of transduced 
Cre-expressing 293 cells. Of those cells, approximately 70% 
transduction efficiency was achieved by Rep-mediated site-
specific integration. 
 The finding that concatameric plasmid replication 
products from the AAV p5 replication origin can be 
packaged into HSV-1 virions if HSV-1 pac is included on 
the plasmid [108]  could lead to the construction of a novel 
generation of HSV/AAV hybrid amplicon vectors which 
replicate from a heterologous origin of DNA replication. 
Such a vector system would have several advantages: first, 
as described by Philpott and coworkers, the AAV p5 element 
can efficiently mediate site-specific vector integration into 
AAVS1 on human chromosome 19 and support long term 
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transgene expression [144, 225]. Second, the AAV p5 
replication origin is not inhibited by rep expression, but 
instead depends on the presence of AAV Rep protein in the 
replication/packaging process [108, 116, 117]. 
 The HSV-1 virion contains three proteinaceous 
compartments for delivery - envelope, tegument, and capsid 
– which could all be used to deliver functional foreign 
proteins by fusion with virion components [226]. For 
example, AAV Rep could be fused with VP16, an abundant 
HSV-1 tegument protein that enters the cell nucleus along 
with the virus genome. This would allow eliminating the rep 
gene from the HSV/AAV hybrid vector genome, as Rep 
protein could enter the cell nucleus as a fusion with VP16 
and there may mediate efficient site-specific integration of 
the transgene sequences via p5 or ITRs. 
 The full potential of HSV/AAV hybrid vectors still needs 
to be evaluated for site-specific integration in vivo, for 
example in transgenic mice that carry the human-specific 
AAVS1 genomic element [227]. As murine [228]  and 
simian [229]  AAVS1 orthologs have been found, AAV2 
likely can mediate site-specific integration in other species as 
well. 
 Future perspective and clinical use of HSV/AAV hybrid 
vectors are closely linked to standard HSV-1 amplicon 
vectors as both vector systems depend on the same 
packaging procedure. Helper virus-free packaging systems 
require transient transfection of vector DNA and packaging-
defective HSV-1 helper DNA, which limits scale up 
potential. The use of amplicon vectors for clinical trials 
depends, therefore, on the design of novel packaging 
procedures that allow the production of large amounts of 
vector stocks with high titers. Strategies to overcome the 
adverse effects of the AAV rep gene on the titers of 
HSV/AAV hybrid vectors have been discussed above. The 
presence of the genetic elements from AAV on HSV-1 
amplicon vectors should not add additional safety concerns 
to the amplicon system, as AAV is not known to be 
pathogenic in humans and AAV vectors are already being 
used in clinical trials. 
OTHER HYBRID AMPLICON VECTORS 
HSV/EBV Hybrid Vectors 
 Epstein-Barr virus, a human Gammaherpesvirus, has also 
been used as a hybrid partner with HSV-1 amplicons, due to 
its potential to persist as an extrachromosomal element in B-
lymphocytes [230]. The EBV nuclear antigen (EBNA-1) and 
the origin of DNA replication (oriP) are the sole elements 
necessary for the long-term episomal retention and are 
therefore incorporated into the HSV-1 amplicon backbone to 
support replication and mitotic segregation of the amplicon 
concatenate in the host cell nucleus [231, 232]  (Fig. 2D). 
HSV/EBV hybrid amplicon vectors have been demonstrated 
to efficiently transduce various human cells in culture and to 
support retention of vector sequences in dividing human 
cells [205]. Stable expression from large transgenes has also 
been demonstrated [233, 234]. Maintenance of transgene 
DNA in an episomal state as opposed to genomic integration 
reduces adverse effects in the host cell. However, long-term 
expression by these vectors depends on selective pressure 
and expression of EBNA-1 [95, 235]. In order to circumvent 
the potential immunogenic and oncogenic properties of 
EBNA-1 [236], the use of a human episomal retention 
element (scaffold/matrix attachment region (S/MAR) from 
the human -interferon gene to generate a novel HSV-1 
amplicon-based episomal vector has shown great potential 
even in the absence of selection pressure [93]. 
HSV/RV Hybrid Vectors 
 Elements from retroviruses (RV) have been combined 
with HSV-1 amplicons in order to achieve prolonged 
transduction of transgenes. Retroviruses, such as Moloney 
murine leukaemia virus (MoMLV), integrate randomly into 
the genome of dividing cells, and produce viral progeny 
without killing the host cell [237]. Due to the low efficiency 
of gene transfer, MoMLV –based vectors have been mostly 
used for ex vivo gene therapy protocols [238, 239]. Although 
this strategy has shown some therapeutic success in 
experimental brain tumors [240, 241]  it is not effective 
when used in human trials [242-245]. HSV/RV hybrid 
amplicon vectors containing genetic elements from MoMLV 
have been developed in order to transduce genes required for 
the de novo synthesis of small defective retrovirus vectors. 
These hybrid vectors contain the long terminal repeat 
sequences (LTRs) flanking a transgene cassette, and the gag, 
pol, and env genes in a separate cassette (Fig. 2E). The LTRs 
and psi sequence comprise the signals necessary for 
packaging of virion RNA, reverse transcription, and 
integration into host cell genome. HSV/MoMLV hybrid 
vectors have indeed been demonstrated to support the 
packaging of genomic retrovirus RNA expressed from the 
amplicon vector into MoMLV particles and accomplish 
integration and transgenic expression in infected naïve cells 
[246]. One point of caution, however, is the danger of 
endogenous retroviruses complementing retroviral elements 
in hybrid vectors. The possibility that endogenous integrases 
can act on LTRs in hybrid amplicon vectors has indeed been 
demonstrated [247]. In order to enhance the transduction 
efficiency of a therapeutic gene in vivo and increase its 
expression stability, hybrid vectors containing elements from 
more than 2 viruses have been developed as well. These 
tribid vectors are based on HSV-1 amplicon vectors and 
contain elements from MoMLV and either EBV or AAV 
[205, 248]. 
REFERENCES 
[1] Davison MD, Rixon FJ, Davison AJ. Identification of genes 
encoding two capsid proteins (VP24 and VP26) of herpes simplex 
virus type 1. J Gen Virol 1992; 73 (Pt 10): 2709-13. 
[2] Beard PM, Taus NS, Baines JD. DNA cleavage and packaging 
proteins encoded by genes U(L)28, U(L)15, and U(L)33 of herpes 
simplex virus type 1 form a complex in infected cells. J Virol 2002; 
76: 4785-91. 
[3] Jacobson JG, Yang K, Baines JD, Homa FL. Linker insertion 
mutations in the herpes simplex virus type 1 UL28 gene: effects on 
UL28 interaction with UL15 and UL33 and identification of a 
second-site mutation in the UL15 gene that suppresses a lethal 
UL28 mutation. J Virol 2006; 80: 12312-23. 
[4] Newcomb WW, Homa FL, Brown JC. Herpes simplex virus capsid 
structure: DNA packaging protein UL25 is located on the external 
surface of the capsid near the vertices. J Virol 2006; 80: 6286-94. 
[5] Thurlow JK, Murphy M, Stow ND, Preston VG. Herpes simplex 
virus type 1 DNA-packaging protein UL17 is required for efficient 
binding of UL25 to capsids. J Virol 2006; 80: 2118-26. 
[6] Trus BL, Newcomb WW, Cheng N, et al. Allosteric signaling and 
a nuclear exit strategy: binding of UL25/UL17 heterodimers to 
DNA-Filled HSV-1 capsids. Mol Cell 2007; 26: 479-89. 
HSV/AAV Hybrid Vectors The Open Virology Journal, 2010, Volume 4    117 
[7] Copeland AM, Newcomb WW, Brown JC. Herpes simplex virus 
replication: roles of viral proteins and nucleoporins in capsid-
nucleus attachment. J Virol 2009; 83: 1660-8. 
[8] Jovasevic V, Liang L, Roizman B. Proteolytic cleavage of VP1-2 is 
required for release of herpes simplex virus 1 DNA into the 
nucleus. J Virol 2008; 82: 3311-9. 
[9] Amici C, Rossi A, Costanzo A, et al. Herpes simplex virus disrupts 
NF-kappaB regulation by blocking its recruitment on the 
IkappaBalpha promoter and directing the factor on viral genes. J 
Biol Chem 2006; 281: 7110-7. 
[10] Barzilai A, Zivony-Elbom I, Sarid R, Noah E, Frenkel N. The 
herpes simplex virus type 1 vhs-UL41 gene secures viral 
replication by temporarily evading apoptotic cellular response to 
infection: Vhs-UL41 activity might require interactions with 
elements of cellular mRNA degradation machinery. J Virol 2006; 
80: 505-13. 
[11] Duffy C, Mbong EF, Baines JD. VP22 of herpes simplex virus 1 
promotes protein synthesis at late times in infection and accumu-
lation of a subset of viral mRNAs at early times in infection. J 
Virol 2009; 83: 1009-17. 
[12] Kwong AD, Kruper JA, Frenkel N. Herpes simplex virus virion 
host shutoff function. J Virol 1988; 62: 912-21. 
[13] Liu X, Fitzgerald K, Kurt-Jones E, Finberg R, Knipe DM. 
Herpesvirus tegument protein activates NF-kappaB signaling 
through the TRAF6 adaptor protein. Proc Natl Acad Sci USA 
2008; 105: 11335-9. 
[14] Strom T, Frenkel N. Effects of herpes simplex virus on mRNA 
stability. J Virol 1987; 61: 2198-207. 
[15] Campadelli-Fiume G, Amasio M, Avitabile E, et al. The multi-
partite system that mediates entry of herpes simplex virus into the 
cell. Rev Med Virol 2007; 17: 313-26. 
[16] Polcicova K, Goldsmith K, Rainish BL, Wisner TW, Johnson DC. 
The extracellular domain of herpes simplex virus gE is 
indispensable for efficient cell-to-cell spread: evidence for gE/gI 
receptors. J Virol 2005; 79: 11990-2001. 
[17] Campadelli-Fiume G, Qi S, Avitabile E, Foa-Tomasi L, Brandimarti R, 
Roizman B. Glycoprotein D of herpes simplex virus encodes a domain 
which precludes penetration of cells expressing the glycoprotein by 
superinfecting herpes simplex virus. J Virol 1990; 64: 6070-9. 
[18] Desai PJ, Schaffer PA, Minson AC. Excretion of non-infectious 
virus particles lacking glycoprotein H by a temperature-sensitive 
mutant of herpes simplex virus type 1: evidence that gH is essential 
for virion infectivity. J Gen Virol 1988; 69 (Pt 6): 1147-56. 
[19] Shukla D, Spear PG. Herpesviruses and heparan sulfate: an 
intimate relationship in aid of viral entry. J Clin Invest 2001; 108: 
503-10. 
[20] Spear PG, Eisenberg RJ, Cohen GH. Three classes of cell surface 
receptors for alphaherpesvirus entry. Virology 2000; 275: 1-8. 
[21] Favoreel HW. The why's of Y-based motifs in alphaherpesvirus 
envelope proteins. Virus Res 2006; 117: 202-8. 
[22] Nicola AV, McEvoy AM, Straus SE. Roles for endocytosis and 
low pH in herpes simplex virus entry into HeLa and Chinese 
hamster ovary cells. J Virol 2003; 77: 5324-32. 
[23] Clement C, Tiwari V, Scanlan PM, Valyi-Nagy T, Yue BY, Shukla 
D. A novel role for phagocytosis-like uptake in herpes simplex 
virus entry. J Cell Biol 2006; 174: 1009-21. 
[24] Dohner K, Radtke K, Schmidt S, Sodeik B. Eclipse phase of herpes 
simplex virus type 1 infection: Efficient dynein-mediated capsid 
transport without the small capsid protein VP26. J Virol 2006; 80: 
8211-24. 
[25] Dohner K, Wolfstein A, Prank U, et al. Function of dynein and 
dynactin in herpes simplex virus capsid transport. Mol Biol Cell 
2002; 13: 2795-809. 
[26] Sodeik B, Ebersold MW, Helenius A. Microtubule-mediated 
transport of incoming herpes simplex virus 1 capsids to the 
nucleus. J Cell Biol 1997; 136: 1007-21. 
[27] Ojala PM, Sodeik B, Ebersold MW, Kutay U, Helenius A. Herpes 
simplex virus type 1 entry into host cells: reconstitution of capsid 
binding and uncoating at the nuclear pore complex in vitro. Mol 
Cell Biol 2000; 20: 4922-31. 
[28] Shahin V, Hafezi W, Oberleithner H, et al. The genome of HSV-1 
translocates through the nuclear pore as a condensed rod-like 
structure. J Cell Sci 2006; 119: 23-30. 
[29] Lockshon D, Galloway DA. Cloning and characterization of oriL2, 
a large palindromic DNA replication origin of herpes simplex virus 
type 2. J Virol 1986; 58: 513-21. 
[30] Stow ND. Localization of an origin of DNA replication within the 
TRS/IRS repeated region of the herpes simplex virus type 1 
genome. EMBO J 1982; 1: 863-7. 
[31] Roizman B, Sears AE. Herpes simplex viruses and their replication. 
New York, N.Y.: Raven Press, Ltd; 1996. 
[32] Garber DA, Beverley SM, Coen DM. Demonstration of 
circularization of herpes simplex virus DNA following infection 
using pulsed field gel electrophoresis. Virology 1993; 197: 459-62. 
[33] Jackson SA, DeLuca NA. Relationship of herpes simplex virus 
genome configuration to productive and persistent infections. Proc 
Natl Acad Sci USA 2003; 100: 7871-6. 
[34] Ben-Porat T, Tokazewski SA. Replication of herpesvirus DNA. II. 
Sedimentation characteristics of newly synthesized DNA. Virology 
1977; 79: 292-301. 
[35] Jacob RJ, Morse LS, Roizman B. Anatomy of herpes simplex virus 
DNA. XII. Accumulation of head-to-tail concatemers in nuclei of 
infected cells and their role in the generation of the four isomeric 
arrangements of viral DNA. J Virol 1979; 29: 448-57. 
[36] Jacob RJ, Roizman B. Anatomy of herpes simplex virus DNA VIII. 
Properties of the replicating DNA. J Virol 1977; 23: 394-411. 
[37] Deiss LP, Frenkel N. Herpes simplex virus amplicon: cleavage of 
concatemeric DNA is linked to packaging and involves 
amplification of the terminally reiterated a sequence. J Virol 1986; 
57: 933-41. 
[38] Roizman B. The function of herpes simplex virus genes: a primer 
for genetic engineering of novel vectors. Proc Natl Acad Sci USA 
1996; 93: 11307-12. 
[39] Conley AJ, Knipe DM, Jones PC, Roizman B. Molecular genetics 
of herpes simplex virus. VII. Characterization of a temperature-
sensitive mutant produced by in vitro mutagenesis and defective in 
DNA synthesis and accumulation of gamma polypeptides. J Virol 
1981; 37: 191-206. 
[40] Honess RW, Roizman B. Regulation of herpesvirus 
macromolecular synthesis. I. Cascade regulation of the synthesis of 
three groups of viral proteins. J Virol 1974; 14: 8-19. 
[41] Browne H, Bell S, Minson T, Wilson DW. An endoplasmic 
reticulum-retained herpes simplex virus glycoprotein H is absent 
from secreted virions: evidence for reenvelopment during egress. J 
Virol 1996; 70: 4311-6. 
[42] Skepper JN, Whiteley A, Browne H, Minson A. Herpes simplex 
virus nucleocapsids mature to progeny virions by an envelopment -
-> deenvelopment --> reenvelopment pathway. J Virol 2001; 75: 
5697-702. 
[43] Beitia Ortiz de Zarate I, Kaelin K, Rozenberg F. Effects of 
mutations in the cytoplasmic domain of herpes simplex virus type 1 
glycoprotein B on intracellular transport and infectivity. J Virol 
2004; 78: 1540-51. 
[44] Harley CA, Dasgupta A, Wilson DW. Characterization of herpes 
simplex virus-containing organelles by subcellular fractionation: 
role for organelle acidification in assembly of infectious particles. J 
Virol 2001; 75: 1236-51. 
[45] Johnson DC, Webb M, Wisner TW, Brunetti C. Herpes simplex 
virus gE/gI sorts nascent virions to epithelial cell junctions, 
promoting virus spread. J Virol 2001; 75: 821-33. 
[46] McMillan TN, Johnson DC. Cytoplasmic domain of herpes simplex 
virus gE causes accumulation in the trans-Golgi network, a site of 
virus envelopment and sorting of virions to cell junctions. J Virol 
2001; 75: 1928-40. 
[47] Mettenleiter TC, Klupp BG, Granzow H. Herpesvirus assembly: an 
update. Virus Res 2009; 143: 222-34. 
[48] Turcotte S, Letellier J, Lippe R. Herpes simplex virus type 1 
capsids transit by the trans-Golgi network, where viral 
glycoproteins accumulate independently of capsid egress. J Virol 
2005; 79: 8847-60. 
[49] Whiteley A, Bruun B, Minson T, Browne H. Effects of targeting 
herpes simplex virus type 1 gD to the endoplasmic reticulum and 
trans-Golgi network. J Virol 1999; 73: 9515-20. 
[50] Leuzinger H, Ziegler U, Schraner EM, et al. Herpes simplex virus 
1 envelopment follows two diverse pathways. J Virol 2005; 79: 
13047-59. 
[51] Wild P, Engels M, Senn C, et al. Impairment of nuclear pores in 
bovine herpesvirus 1-infected MDBK cells. J Virol 2005; 79: 1071-
83. 
[52] Wild P, Schraner EM, Cantieni D, et al. The significance of the 
Golgi complex in envelopment of bovine herpesvirus 1 (BHV-1) as 
118    The Open Virology Journal, 2010, Volume 4 de Oliveira and Fraefel 
revealed by cryobased electron microscopy. Micron 2002; 33: 327-
37. 
[53] Avitabile E, Di Gaeta S, Torrisi MR, Ward PL, Roizman B, 
Campadelli-Fiume G. Redistribution of microtubules and Golgi 
apparatus in herpes simplex virus-infected cells and their role in 
viral exocytosis. J Virol 1995; 69: 7472-82. 
[54] Brunetti CR, Dingwell KS, Wale C, Graham FL, Johnson DC. 
Herpes simplex virus gD and virions accumulate in endosomes by 
mannose 6-phosphate-dependent and -independent mechanisms. J 
Virol 1998; 72: 3330-9. 
[55] Whealy ME, Card JP, Meade RP, Robbins AK, Enquist LW. Effect 
of brefeldin A on alphaherpesvirus membrane protein glycosylation 
and virus egress. J Virol 1991; 65: 1066-81. 
[56] Steiner I, Spivack JG, Deshmane SL, Ace CI, Preston CM, Fraser 
NW. A herpes simplex virus type 1 mutant containing a 
nontransinducing Vmw65 protein establishes latent infection in 
vivo in the absence of viral replication and reactivates efficiently 
from explanted trigeminal ganglia. J Virol 1990; 64: 1630-8. 
[57] Preston CM. Repression of viral transcription during herpes 
simplex virus latency. J Gen Virol 2000; 81: 1-19. 
[58] Thompson RL, Sawtell NM. The herpes simplex virus type 1 
latency-associated transcript gene regulates the establishment of 
latency. J Virol 1997; 71: 5432-40. 
[59] Bloom DC, Hill JM, Devi-Rao G, Wagner EK, Feldman LT, 
Stevens JG. A 348-base-pair region in the latency-associated 
transcript facilitates herpes simplex virus type 1 reactivation. J 
Virol 1996; 70: 2449-59. 
[60] Hill JM, Garza HH, Jr., Su YH, et al. A 437-base-pair deletion at 
the beginning of the latency-associated transcript promoter 
significantly reduced adrenergically induced herpes simplex virus 
type 1 ocular reactivation in latently infected rabbits. J Virol 1997; 
71: 6555-9. 
[61] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and 
function. Cell 2004; 116: 281-97. 
[62] Murphy E, Vanicek J, Robins H, Shenk T, Levine AJ. Suppression 
of immediate-early viral gene expression by herpesvirus-coded 
microRNAs: implications for latency. Proc Natl Acad Sci USA 
2008; 105: 5453-8. 
[63] Randall G, Roizman B. Transcription of the derepressed open 
reading frame P of herpes simplex virus 1 precludes the expression 
of the antisense gamma(1)34.5 gene and may account for the 
attenuation of the mutant virus. J Virol 1997; 71: 7750-7. 
[64] Umbach JL, Kramer MF, Jurak I, Karnowski HW, Coen DM, 
Cullen BR. MicroRNAs expressed by herpes simplex virus 1 
during latent infection regulate viral mRNAs. Nature 2008; 454: 
780-3. 
[65] Yeh L, Schaffer PA. A novel class of transcripts expressed with 
late kinetics in the absence of ICP4 spans the junction between the 
long and short segments of the herpes simplex virus type 1 genome. 
J Virol 1993; 67: 7373-82. 
[66] Amelio AL, McAnany PK, Bloom DC. A chromatin insulator-like 
element in the herpes simplex virus type 1 latency-associated 
transcript region binds CCCTC-binding factor and displays 
enhancer-blocking and silencing activities. J Virol 2006; 80: 2358-
68. 
[67] Jordan R, Schaffer PA. Activation of gene expression by herpes 
simplex virus type 1 ICP0 occurs at the level of mRNA synthesis. J 
Virol 1997; 71: 6850-62. 
[68] Pesola JM, Zhu J, Knipe DM, Coen DM. Herpes simplex virus 1 
immediate-early and early gene expression during reactivation 
from latency under conditions that prevent infectious virus 
production. J Virol 2005; 79: 14516-25. 
[69] Sawtell NM, Thompson RL, Haas RL. Herpes simplex virus DNA 
synthesis is not a decisive regulatory event in the initiation of lytic 
viral protein expression in neurons in vivo during primary infection 
or reactivation from latency. J Virol 2006; 80: 38-50. 
[70] Thompson RL, Sawtell NM. Evidence that the herpes simplex virus 
type 1 ICP0 protein does not initiate reactivation from latency in 
vivo. J Virol 2006; 80: 10919-30. 
[71] Thompson RL, Preston CM, Sawtell NM. De novo synthesis of 
VP16 coordinates the exit from HSV latency in vivo. PLoS Pathog 
2009; 5: e1000352. 
[72] Krisky DM, Marconi PC, Oligino T, Rouse RJ, Fink DJ, Glorioso 
JC. Rapid method for construction of recombinant HSV gene 
transfer vectors. Gene Ther 1997; 4: 1120-5. 
[73] Cuchet D, Potel C, Thomas J, Epstein AL. HSV-1 amplicon 
vectors: a promising and versatile tool for gene delivery. Expert 
Opin Biol Ther 2007; 7: 975-95. 
[74] Spaete RR, Frenkel N. The herpes simplex virus amplicon: a new 
eucaryotic defective-virus cloning-amplifying vector. Cell 1982; 
30: 295-304. 
[75] Spaete RR, Frenkel N. The herpes simplex virus amplicon: 
analyses of cis-acting replication functions. Proc Natl Acad Sci 
USA 1985; 82: 694-8. 
[76] Kwong AD, Frenkel N. Biology of herpes symplex virus (HSV) 
defective viruses and development of the amplicon system. New 
York: Academic Press; 1998. 
[77] Lu B, Federoff HJ, Wang Y, Goldsmith LA, Scott G. Topical 
application of viral vectors for epidermal gene transfer. J Invest 
Dermatol 1997; 108: 803-8. 
[78] Willis RA, Bowers WJ, Turner MJ, et al. Dendritic cells transduced 
with HSV-1 amplicons expressing prostate-specific antigen 
generate antitumor immunity in mice. Hum Gene Ther 2001; 12: 
1867-79. 
[79] Bowers WJ, Chen X, Guo H, Frisina DR, Federoff HJ, Frisina RD. 
Neurotrophin-3 transduction attenuates cisplatin spiral ganglion 
neuron ototoxicity in the cochlea. Mol Ther 2002; 6: 12-8. 
[80] Derby ML, Sena-Esteves M, Breakefield XO, Corey DP. Gene 
transfer into the mammalian inner ear using HSV-1 and vaccinia 
virus vectors. Hear Res 1999; 134: 1-8. 
[81] Fraefel C, Jacoby DR, Lage C, et al. Gene transfer into hepatocytes 
mediated by helper virus-free HSV/AAV hybrid vectors. Mol Med 
1997; 3: 813-25. 
[82] Wang Y, Mukherjee S, Fraefel C, Breakefield XO, Allen PD. 
Herpes simplex virus type 1 amplicon vector-mediated gene 
transfer to muscle. Hum Gene Ther 2002; 13: 261-73. 
[83] Neve RL, Neve KA, Nestler EJ, Carlezon WA, Jr. Use of herpes 
virus amplicon vectors to study brain disorders. Biotechniques 
2005; 39: 381-91. 
[84] Saydam O, Glauser DL, Heid I, et al. Herpes simplex virus 1 
amplicon vector-mediated siRNA targeting epidermal growth 
factor receptor inhibits growth of human glioma cells in vivo. Mol 
Ther 2005; 12: 803-12. 
[85] Saydam O, Saydam N, Glauser DL, et al. HSV-1 amplicon-
mediated post-transcriptional inhibition of Rad51 sensitizes human 
glioma cells to ionizing radiation. Gene Ther 2007; 14: 1143-51. 
[86] Shah K, Tung CH, Chang CH, et al. In vivo imaging of HIV 
protease activity in amplicon vector-transduced gliomas. Cancer 
Res 2004; 64: 273-8. 
[87] Suzuki M, Kasai K, Saeki Y. Plasmid DNA sequences present in 
conventional herpes simplex virus amplicon vectors cause rapid 
transgene silencing by forming inactive chromatin. J Virol 2006; 
80: 3293-300. 
[88] Kaplitt MG, Kwong AD, Kleopoulos SP, Mobbs CV, Rabkin SD, 
Pfaff DW. Preproenkephalin promoter yields region-specific and 
long-term expression in adult brain after direct in vivo gene transfer 
via a defective herpes simplex viral vector. Proc Natl Acad Sci 
USA 1994; 91: 8979-83. 
[89] Song S, Wang Y, Bak SY, et al. An HSV-1 vector containing the 
rat tyrosine hydroxylase promoter enhances both long-term and cell 
type-specific expression in the midbrain. J Neurochem 1997; 68: 
1792-803. 
[90] Bowers WJ, Mastrangelo MA, Howard DF, Southerland HA, 
Maguire-Zeiss KA, Federoff HJ. Neuronal precursor-restricted 
transduction via in utero CNS gene delivery of a novel bipartite 
HSV amplicon/transposase hybrid vector. Mol Ther 2006; 13: 580-
8. 
[91] Heister T, Heid I, Ackermann M, Fraefel C. Herpes simplex virus 
type 1/adeno-associated virus hybrid vectors mediate site-specific 
integration at the adeno-associated virus preintegration site, 
AAVS1, on human chromosome 19. J Virol 2002; 76: 7163-73. 
[92] Lufino MM, Edser PA, Wade-Martins R. Advances in high-
capacity extrachromosomal vector technology: episomal 
maintenance, vector delivery, and transgene expression. Mol Ther 
2008; 16: 1525-38. 
[93] Lufino MM, Manservigi R, Wade-Martins R. An S/MAR-based 
infectious episomal genomic DNA expression vector provides 
long-term regulated functional complementation of LDLR 
deficiency. Nucleic Acids Res 2007; 35: e98. 
HSV/AAV Hybrid Vectors The Open Virology Journal, 2010, Volume 4    119 
[94] Moralli D, Simpson KM, Wade-Martins R, Monaco ZL. A novel 
human artificial chromosome gene expression system using herpes 
simplex virus type 1 vectors. EMBO Rep 2006; 7: 911-8. 
[95] Muller L, Saydam O, Saeki Y, Heid I, Fraefel C. Gene transfer into 
hepatocytes mediated by herpes simplex virus-Epstein-Barr virus 
hybrid amplicons. J Virol Methods 2005; 123: 65-72. 
[96] Berns KI, Giraud C. Biology of adeno-associated virus. Curr Top 
Microbiol Immunol 1996; 218: 1-23. 
[97] Bantel-Schaal U, zur Hausen H. Characterization of the DNA of a 
defective human parvovirus isolated from a genital site. Virology 
1984; 134: 52-63. 
[98] Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of 
serum antibodies (IgG and IgM) to adeno-associated virus (AAV). 
J Med Virol 1999; 59: 406-11. 
[99] Parks WP, Boucher DW, Melnick JL, Taber LH, Yow MD. 
Seroepidemiological and Ecological Studies of the Adenovirus-
Associated Satellite Viruses. Infect Immun 1970; 2: 716-22. 
[100] Rutledge EA, Halbert CL, Russell DW. Infectious clones and 
vectors derived from adeno-associated virus (AAV) serotypes other 
than AAV type 2. J Virol 1998; 72: 309-19. 
[101] Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson 
JM. Gene therapy vectors based on adeno-associated virus type 1. J 
Virol 1999; 73: 3994-4003. 
[102] Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes 
of AAV vectors. Curr Gene Ther 2005; 5: 285-97. 
[103] Halbert CL, Rutledge EA, Allen JM, Russell DW, Miller AD. 
Repeat transduction in the mouse lung by using adeno-associated 
virus vectors with different serotypes. J Virol 2000; 74: 1524-32. 
[104] Peden CS, Burger C, Muzyczka N, Mandel RJ. Circulating anti-
wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit 
recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, 
gene transfer in the brain. J Virol 2004; 78: 6344-59. 
[105] Ni TH, McDonald WF, Zolotukhin I, et al. Cellular proteins 
required for adeno-associated virus DNA replication in the absence 
of adenovirus coinfection. J Virol 1998; 72: 2777-87. 
[106] Francois A, Guilbaud M, Awedikian R, Chadeuf G, Moullier P, 
Salvetti A. The cellular TATA binding protein is required for rep-
dependent replication of a minimal adeno-associated virus type 2 
p5 element. J Virol 2005; 79: 11082-94. 
[107] Pereira DJ, McCarty DM, Muzyczka N. The adeno-associated virus 
(AAV) Rep protein acts as both a repressor and an activator to 
regulate AAV transcription during a productive infection. J Virol 
1997; 71: 1079-88. 
[108] Glauser DL, Saydam O, Balsiger NA, et al. Four-dimensional 
visualization of the simultaneous activity of alternative adeno-
associated virus replication origins. J Virol 2005; 79: 12218-30. 
[109] Kyostio SR, Owens RA, Weitzman MD, Antoni BA, Chejanovsky 
N, Carter BJ. Analysis of adeno-associated virus (AAV) wild-type 
and mutant Rep proteins for their abilities to negatively regulate 
AAV p5 and p19 mRNA levels. J Virol 1994; 68: 2947-57. 
[110] Linden RM, Berns KI. Molecular biology of adeno-associated 
viruses. Contrib Microbiol 2000; 4: 68-84. 
[111] McCarty DM, Young SM, Jr., Samulski RJ. Integration of adeno-
associated virus (AAV) and recombinant AAV vectors. Annu Rev 
Genet 2004; 38: 819-45. 
[112] Ward P, Berns KI. Minimum origin requirements for linear duplex 
AAV DNA replication in vitro. Virology 1995; 209: 692-5. 
[113] Ward P, Falkenberg M, Elias P, Weitzman M, Linden RM. Rep-
dependent initiation of adeno-associated virus type 2 DNA 
replication by a herpes simplex virus type 1 replication complex in 
a reconstituted system. J Virol 2001; 75: 10250-8. 
[114] Ward P, Berns KI. In vitro replication of adeno-associated virus 
DNA: enhancement by extracts from adenovirus-infected HeLa 
cells. J Virol 1996; 70: 4495-501. 
[115] Hong G, Ward P, Berns KI. Intermediates of adeno-associated 
virus DNA replication in vitro. J Virol 1994; 68: 2011-5. 
[116] Musatov S, Roberts J, Pfaff D, Kaplitt M. A cis-acting element that 
directs circular adeno-associated virus replication and packaging. J 
Virol 2002; 76: 12792-802. 
[117] Nony P, Tessier J, Chadeuf G, et al. Novel cis-acting replication 
element in the adeno-associated virus type 2 genome is involved in 
amplification of integrated rep-cap sequences. J Virol 2001; 75: 
9991-4. 
[118] Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA 
viruses found in various adenovirus preparations: physical, 
biological, and immunological characteristics. Proc Natl Acad Sci 
USA 1966; 55: 1467-74. 
[119] Buller RM, Janik JE, Sebring ED, Rose JA. Herpes simplex virus 
types 1 and 2 completely help adenovirus-associated virus 
replication. J Virol 1981; 40: 241-7. 
[120] McPherson RA, Rosenthal LJ, Rose JA. Human cytomegalovirus 
completely helps adeno-associated virus replication. Virology 
1985; 147: 217-22. 
[121] Shiau AL, Liu PS, Wu CL. Novel strategy for generation and 
titration of recombinant adeno-associated virus vectors. J Virol 
2005; 79: 193-201. 
[122] Schlehofer JR, Ehrbar M, zur Hausen H. Vaccinia virus, herpes 
simplex virus, and carcinogens induce DNA amplification in a 
human cell line and support replication of a helpervirus dependent 
parvovirus. Virology 1986; 152: 110-7. 
[123] Grifman M, Chen NN, Gao GP, Cathomen T, Wilson JM, 
Weitzman MD. Overexpression of cyclin A inhibits augmentation 
of recombinant adeno-associated virus transduction by the 
adenovirus E4orf6 protein. J Virol 1999; 73: 10010-9. 
[124] Roizman B, Roane PR, Jr. The Multiplication Of Herpes Simplex 
Virus. Ii. The Relation Between Protein Synthesis And The 
Duplication Of Viral Dna In Infected Hep-2 Cells. Virology 1964; 
22: 262-9. 
[125] Taddeo B, Esclatine A, Roizman B. Post-transcriptional processing 
of cellular RNAs in herpes simplex virus-infected cells. Biochem 
Soc Trans 2004; 32: 697-701. 
[126] Heilbronn R, Engstler M, Weger S, Krahn A, Schetter C, Boshart 
M. ssDNA-dependent colocalization of adeno-associated virus Rep 
and herpes simplex virus ICP8 in nuclear replication domains. 
Nucleic Acids Res 2003; 31: 6206-13. 
[127] Slanina H, Weger S, Stow ND, Kuhrs A, Heilbronn R. Role of the 
herpes simplex virus helicase-primase complex during adeno-
associated virus DNA replication. J Virol 2006; 80: 5241-50. 
[128] Stracker TH, Cassell GD, Ward P, et al. The Rep protein of adeno-
associated virus type 2 interacts with single-stranded DNA-binding 
proteins that enhance viral replication. J Virol 2004; 78: 441-53. 
[129] Weindler FW, Heilbronn R. A subset of herpes simplex virus 
replication genes provides helper functions for productive adeno-
associated virus replication. J Virol 1991; 65: 2476-83. 
[130] Alazard-Dany N, Nicolas A, Ploquin A, et al. Definition of herpes 
simplex virus type 1 helper activities for adeno-associated virus 
early replication events. PLoS Pathog 2009; 5: e1000340. 
[131] Glauser DL, Strasser R, Laimbacher AS, et al. Live covisualization 
of competing adeno-associated virus and herpes simplex virus type 
1 DNA replication: molecular mechanisms of interaction. J Virol 
2007; 81: 4732-43. 
[132] Heilbronn R, Burkle A, Stephan S, zur Hausen H. The adeno-
associated virus rep gene suppresses herpes simplex virus-induced 
DNA amplification. J Virol 1990; 64: 3012-8. 
[133] Kotin RM, Linden RM, Berns KI. Characterization of a preferred 
site on human chromosome 19q for integration of adeno-associated 
virus DNA by non-homologous recombination. EMBO J 1992; 11: 
5071-8. 
[134] Samulski RJ, Zhu X, Xiao X, et al. Targeted integration of adeno-
associated virus (AAV) into human chromosome 19. EMBO J 
1991; 10: 3941-50. 
[135] Surosky RT, Urabe M, Godwin SG, et al. Adeno-associated virus 
Rep proteins target DNA sequences to a unique locus in the human 
genome. J Virol 1997; 71: 7951-9. 
[136] Weitzman MD, Kyostio SR, Kotin RM, Owens RA. Adeno-
associated virus (AAV) Rep proteins mediate complex formation 
between AAV DNA and its integration site in human DNA. Proc 
Natl Acad Sci USA 1994; 91: 5808-12. 
[137] Dyall J, Berns KI. Site-specific integration of adeno-associated 
virus into an episome with the target locus via a deletion-
substitution mechanism. J Virol 1998; 72: 6195-8. 
[138] Giraud C, Winocour E, Berns KI. Site-specific integration by 
adeno-associated virus is directed by a cellular DNA sequence. 
Proc Natl Acad Sci USA 1994; 91: 10039-43. 
[139] Linden RM, Ward P, Giraud C, Winocour E, Berns KI. Site-
specific integration by adeno-associated virus. Proc Natl Acad Sci 
USA 1996; 93: 11288-94. 
[140] Smith RH. Adeno-associated virus integration: virus vs vector. 
Gene Ther 2008; 15: 817-22. 
120    The Open Virology Journal, 2010, Volume 4 de Oliveira and Fraefel 
[141] Urcelay E, Ward P, Wiener SM, Safer B, Kotin RM. Asymmetric 
replication in vitro from a human sequence element is dependent on 
adeno-associated virus Rep protein. J Virol 1995; 69: 2038-46. 
[142] Young SM, Jr., McCarty DM, Degtyareva N, Samulski RJ. Roles 
of adeno-associated virus Rep protein and human chromosome 19 
in site-specific recombination. J Virol 2000; 74: 3953-66. 
[143] Young SM, Jr., Samulski RJ. Adeno-associated virus (AAV) site-
specific recombination does not require a Rep-dependent origin of 
replication within the AAV terminal repeat. Proc Natl Acad Sci 
USA 2001; 98: 13525-30. 
[144] Philpott NJ, Gomos J, Berns KI, Falck-Pedersen E. A p5 
integration efficiency element mediates Rep-dependent integration 
into AAVS1 at chromosome 19. Proc Natl Acad Sci USA 2002; 99: 
12381-5. 
[145] Feng D, Chen J, Yue Y, Zhu H, Xue J, Jia WW. A 16bp Rep 
binding element is sufficient for mediating Rep-dependent 
integration into AAVS1. J Mol Biol 2006; 358: 38-45. 
[146] Geoffroy MC, Epstein AL, Toublanc E, Moullier P, Salvetti A. 
Herpes simplex virus type 1 ICP0 protein mediates activation of 
adeno-associated virus type 2 rep gene expression from a latent 
integrated form. J Virol 2004; 78: 10977-86. 
[147] Meyers C, Mane M, Kokorina N, Alam S, Hermonat PL. 
Ubiquitous human adeno-associated virus type 2 autonomously 
replicates in differentiating keratinocytes of a normal skin model. 
Virology 2000; 272: 338-46. 
[148] Yakobson B, Hrynko TA, Peak MJ, Winocour E. Replication of 
adeno-associated virus in cells irradiated with UV light at 254 nm. 
J Virol 1989; 63: 1023-30. 
[149] Yalkinoglu AO, Heilbronn R, Burkle A, Schlehofer JR, zur Hausen 
H. DNA amplification of adeno-associated virus as a response to 
cellular genotoxic stress. Cancer Res 1988; 48: 3123-9. 
[150] Summerford C, Samulski RJ. Membrane-associated heparan sulfate 
proteoglycan is a receptor for adeno-associated virus type 2 virions. 
J Virol 1998; 72: 1438-45. 
[151] Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. 
Human fibroblast growth factor receptor 1 is a co-receptor for 
infection by adeno-associated virus 2. Nat Med 1999; 5: 71-7. 
[152] Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: a 
co-receptor for adeno-associated virus type 2 infection. Nat Med 
1999; 5: 78-82. 
[153] Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of 
adeno-associated virus and adeno-associated virus vectors. J Virol 
2000; 74: 2777-85. 
[154] Ding W, Zhang L, Yan Z, Engelhardt JF. Intracellular trafficking of 
adeno-associated viral vectors. Gene Ther 2005; 12: 873-80. 
[155] Ding W, Zhang LN, Yeaman C, Engelhardt JF. rAAV2 traffics 
through both the late and the recycling endosomes in a dose-
dependent fashion. Mol Ther 2006; 13: 671-82. 
[156] Lux K, Goerlitz N, Schlemminger S, et al. Green fluorescent 
protein-tagged adeno-associated virus particles allow the study of 
cytosolic and nuclear trafficking. J Virol 2005; 79: 11776-87. 
[157] Hansen J, Qing K, Srivastava A. Infection of purified nuclei by 
adeno-associated virus 2. Mol Ther 2001; 4: 289-96. 
[158] Daya S, Berns KI. Gene therapy using adeno-associated virus 
vectors. Clin Microbiol Rev 2008; 21: 583-93. 
[159] Kwon I, Schaffer DV. Designer gene delivery vectors: molecular 
engineering and evolution of adeno-associated viral vectors for 
enhanced gene transfer. Pharm Res 2008; 25: 489-99. 
[160] Park K, Kim WJ, Cho YH, et al. Cancer gene therapy using adeno-
associated virus vectors. Front Biosci 2008; 13: 2653-9. 
[161] Conway JE, Rhys CM, Zolotukhin I, et al. High-titer recombinant 
adeno-associated virus production utilizing a recombinant herpes 
simplex virus type I vector expressing AAV-2 Rep and Cap. Gene 
Ther 1999; 6: 986-93. 
[162] Zhang HG, Wang YM, Xie JF, et al. Recombinant adenovirus 
expressing adeno-associated virus cap and rep proteins supports 
production of high-titer recombinant adeno-associated virus. Gene 
Ther 2001; 8: 704-12. 
[163] Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for 
production and purification of recombinant adenoassociated virus 
vectors. Hum Gene Ther 1998; 9: 2745-60. 
[164] Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR. Cell lines 
for the production of recombinant adeno-associated virus. Hum 
Gene Ther 1995; 6: 1329-41. 
[165] Clark KR, Voulgaropoulou F, Johnson PR. A stable cell line 
carrying adenovirus-inducible rep and cap genes allows for 
infectivity titration of adeno-associated virus vectors. Gene Ther 
1996; 3: 1124-32. 
[166] Liu X, Voulgaropoulou F, Chen R, Johnson PR, Clark KR. 
Selective Rep-Cap gene amplification as a mechanism for high-titer 
recombinant AAV production from stable cell lines. Mol Ther 
2000; 2: 394-403. 
[167] Meghrous J, Aucoin MG, Jacob D, Chahal PS, Arcand N, Kamen 
AA. Production of recombinant adeno-associated viral vectors 
using a baculovirus/insect cell suspension culture system: from 
shake flasks to a 20-L bioreactor. Biotechnol Prog 2005; 21: 154-
60. 
[168] Urabe M, Nakakura T, Xin KQ, et al. Scalable generation of high-
titer recombinant adeno-associated virus type 5 in insect cells. J 
Virol 2006; 80: 1874-85. 
[169] Janson C, McPhee S, Bilaniuk L, et al. Clinical protocol. Gene 
therapy of Canavan disease: AAV-2 vector for neurosurgical 
delivery of aspartoacylase gene (ASPA) to the human brain. Hum 
Gene Ther 2002; 13: 1391-412. 
[170] Carter BJ. Adeno-associated virus vectors in clinical trials. Hum 
Gene Ther 2005; 16: 541-50. 
[171] Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene 
therapy with an adeno-associated virus (AAV) borne GAD gene for 
Parkinson's disease: an open label, phase I trial. Lancet 2007; 369: 
2097-105. 
[172] Mandel RJ, Burger C. Clinical trials in neurological disorders using 
AAV vectors: promises and challenges. Curr Opin Mol Ther 2004; 
6: 482-90. 
[173] Mandel RJ, Manfredsson FP, Foust KD, et al. Recombinant adeno-
associated viral vectors as therapeutic agents to treat neurological 
disorders. Mol Ther 2006; 13: 463-83. 
[174] Tenenbaum L, Chtarto A, Lehtonen E, Velu T, Brotchi J, Levivier 
M. Recombinant AAV-mediated gene delivery to the central 
nervous system. J Gene Med 2004; 6(Suppl 1): S212-22. 
[175] Burger C, Gorbatyuk OS, Velardo MJ, et al. Recombinant AAV 
viral vectors pseudotyped with viral capsids from serotypes 1, 2, 
and 5 display differential efficiency and cell tropism after delivery 
to different regions of the central nervous system. Mol Ther 2004; 
10: 302-17. 
[176] Furler S, Paterna JC, Weibel M, Bueler H. Recombinant AAV 
vectors containing the foot and mouth disease virus 2A sequence 
confer efficient bicistronic gene expression in cultured cells and rat 
substantia nigra neurons. Gene Ther 2001; 8: 864-73. 
[177] Landgraf R, Frank E, Aldag JM, et al. Viral vector-mediated gene 
transfer of the vole V1a vasopressin receptor in the rat septum: 
improved social discrimination and active social behaviour. Eur J 
Neurosci 2003; 18: 403-11. 
[178] Wang Y, Camp SM, Niwano M, et al. Herpes simplex virus type 
1/adeno-associated virus rep(+) hybrid amplicon vector improves 
the stability of transgene expression in human cells by site-specific 
integration. J Virol 2002; 76: 7150-62. 
[179] Bartlett JS, Samulski RJ, McCown TJ. Selective and rapid uptake 
of adeno-associated virus type 2 in brain. Hum Gene Ther 1998; 9: 
1181-6. 
[180] Klein RL, Meyer EM, Peel AL, et al. Neuron-specific transduction 
in the rat septohippocampal or nigrostriatal pathway by 
recombinant adeno-associated virus vectors. Exp Neurol 1998; 150: 
183-94. 
[181] McCown TJ, Xiao X, Li J, Breese GR, Samulski RJ. Differential 
and persistent expression patterns of CNS gene transfer by an 
adeno-associated virus (AAV) vector. Brain Res 1996; 713: 99-
107. 
[182] Xu Y, Gu Y, Wu P, Li GW, Huang LY. Efficiencies of transgene 
expression in nociceptive neurons through different routes of 
delivery of adeno-associated viral vectors. Hum Gene Ther 2003; 
14: 897-906. 
[183] Thorsen F, Afione S, Huszthy PC, et al. Adeno-associated virus 
(AAV) serotypes 2, 4 and 5 display similar transduction profiles 
and penetrate solid tumor tissue in models of human glioma. J 
Gene Med 2006; 8: 1131-40. 
[184] Davidson BL, Stein CS, Heth JA, et al. Recombinant adeno-
associated virus type 2, 4, and 5 vectors: transduction of variant 
cell types and regions in the mammalian central nervous system. 
Proc Natl Acad Sci USA 2000; 97: 3428-32. 
[185] Wang C, Wang CM, Clark KR, Sferra TJ. Recombinant AAV 
serotype 1 transduction efficiency and tropism in the murine brain. 
Gene Ther 2003; 10: 1528-34. 
HSV/AAV Hybrid Vectors The Open Virology Journal, 2010, Volume 4    121 
[186] Burger C, Nash K, Mandel RJ. Recombinant adeno-associated viral 
vectors in the nervous system. Hum Gene Ther 2005; 16: 781-91. 
[187] Lo WD, Qu G, Sferra TJ, Clark R, Chen R, Johnson PR. Adeno-
associated virus-mediated gene transfer to the brain: duration and 
modulation of expression. Hum Gene Ther 1999; 10: 201-13. 
[188] Mastakov MY, Baer K, Symes CW, Leichtlein CB, Kotin RM, 
During MJ. Immunological aspects of recombinant adeno-
associated virus delivery to the mammalian brain. J Virol 2002; 76: 
8446-54. 
[189] Herzog RW. Immune responses to AAV capsid: are mice not 
humans after all? Mol Ther 2007; 15: 649-50. 
[190] Lowenstein PR, Mandel RJ, Xiong WD, Kroeger K, Castro MG. 
Immune responses to adenovirus and adeno-associated vectors used 
for gene therapy of brain diseases: the role of immunological 
synapses in understanding the cell biology of neuroimmune 
interactions. Curr Gene Ther 2007; 7: 347-60. 
[191] Muzyczka N, Warrington KH, Jr. Custom adeno-associated virus 
capsids: the next generation of recombinant vectors with novel 
tropism. Hum Gene Ther 2005; 16: 408-16. 
[192] McFarland NR, Lee JS, Hyman BT, McLean PJ. Comparison of 
transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 
8 in the rat nigrostriatal system. J Neurochem 2009; 109: 838-45. 
[193] Rabinowitz JE, Rolling F, Li C, et al. Cross-packaging of a single 
adeno-associated virus (AAV) type 2 vector genome into multiple 
AAV serotypes enables transduction with broad specificity. J Virol 
2002; 76: 791-801. 
[194] Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: 
vector toolkit for human gene therapy. Mol Ther 2006; 14: 316-27. 
[195] Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand 
synthesis is a rate-limiting step for efficient transduction by 
recombinant adeno-associated virus vectors. J Virol 1996; 70: 
3227-34. 
[196] McCarty DM. Self-complementary AAV vectors; advances and 
applications. Mol Ther 2008; 16: 1648-56. 
[197] Wu J, Zhao W, Zhong L, et al. Self-complementary recombinant 
adeno-associated viral vectors: packaging capacity and the role of 
rep proteins in vector purity. Hum Gene Ther 2007; 18: 171-82. 
[198] Clark KR, Liu X, McGrath JP, Johnson PR. Highly purified 
recombinant adeno-associated virus vectors are biologically active 
and free of detectable helper and wild-type viruses. Hum Gene 
Ther 1999; 10: 1031-9. 
[199] Davidoff AM, Ng CY, Sleep S, et al. Purification of recombinant 
adeno-associated virus type 8 vectors by ion exchange 
chromatography generates clinical grade vector stock. J Virol 
Methods 2004; 121: 209-15. 
[200] Kaludov N, Handelman B, Chiorini JA. Scalable purification of 
adeno-associated virus type 2, 4, or 5 using ion-exchange 
chromatography. Hum Gene Ther 2002; 13: 1235-43. 
[201] Zolotukhin S, Potter M, Zolotukhin I, et al. Production and 
purification of serotype 1, 2, and 5 recombinant adeno-associated 
viral vectors. Methods 2002; 28: 158-67. 
[202] Oehmig A, Fraefel C, Breakefield XO, Ackermann M. Herpes 
simplex virus type 1 amplicons and their hybrid virus partners, 
EBV, AAV, and retrovirus. Curr Gene Ther 2004; 4: 385-408. 
[203] Lam PY, Breakefield XO. Hybrid vector designs to control the 
delivery, fate and expression of transgenes. J Gene Med 2000; 2: 
395-408. 
[204] Wang S, Di S, Young WB, Jacobson C, Link CJ, Jr. A novel 
herpesvirus amplicon system for in vivo gene delivery. Gene Ther 
1997; 4: 1132-41. 
[205] Sena-Esteves M, Saeki Y, Camp SM, Chiocca EA, Breakefield 
XO. Single-step conversion of cells to retrovirus vector producers 
with herpes simplex virus-Epstein-Barr virus hybrid amplicons. J 
Virol 1999; 73: 10426-39. 
[206] Chiorini JA, Wendtner CM, Urcelay E, Safer B, Hallek M, Kotin 
RM. High-efficiency transfer of the T cell co-stimulatory molecule 
B7-2 to lymphoid cells using high-titer recombinant adeno-
associated virus vectors. Hum Gene Ther 1995; 6: 1531-41. 
[207] Feudner E, de Alwis M, Thrasher AJ, Ali RR, Fauser S. 
Optimization of recombinant adeno-associated virus production 
using an herpes simplex virus amplicon system. J Virol Methods 
2001; 96: 97-105. 
[208] Mamounas M, Leavitt M, Yu M, Wong-Staal F. Increased titer of 
recombinant AAV vectors by gene transfer with adenovirus 
coupled to DNA-polylysine complexes. Gene Ther 1995; 2: 429-
32. 
[209] Vincent KA, Piraino ST, Wadsworth SC. Analysis of recombinant 
adeno-associated virus packaging and requirements for rep and cap 
gene products. J Virol 1997; 71: 1897-905. 
[210] Booth MJ, Mistry A, Li X, Thrasher A, Coffin RS. Transfection-
free and scalable recombinant AAV vector production using 
HSV/AAV hybrids. Gene Ther 2004; 11: 829-37. 
[211] Conway JE, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ. 
Recombinant adeno-associated virus type 2 replication and 
packaging is entirely supported by a herpes simplex virus type 1 
amplicon expressing Rep and Cap. J Virol 1997; 71: 8780-9. 
[212] Fraefel C, Song S, Lim F, et al. Helper virus-free transfer of herpes 
simplex virus type 1 plasmid vectors into neural cells. J Virol 1996; 
70: 7190-7. 
[213] Logvinoff C, Epstein AL. A novel approach for herpes simplex 
virus type 1 amplicon vector production, using the Cre-loxP 
recombination system to remove helper virus. Hum Gene Ther 
2001; 12: 161-7. 
[214] Zaupa C, Revol-Guyot V, Epstein AL. Improved packaging system 
for generation of high-level noncytotoxic HSV-1 amplicon vectors 
using Cre-loxP site-specific recombination to delete the packaging 
signals of defective helper genomes. Hum Gene Ther 2003; 14: 
1049-63. 
[215] Johnston KM, Jacoby D, Pechan PA, et al. HSV/AAV hybrid 
amplicon vectors extend transgene expression in human glioma 
cells. Hum Gene Ther 1997; 8: 359-70. 
[216] Giraud C, Winocour E, Berns KI. Recombinant junctions formed 
by site-specific integration of adeno-associated virus into an 
episome. J Virol 1995; 69: 6917-24. 
[217] Kotin RM, Siniscalco M, Samulski RJ, et al. Site-specific 
integration by adeno-associated virus. Proc Natl Acad Sci USA 
1990; 87: 2211-5. 
[218] Linden RM, Winocour E, Berns KI. The recombination signals for 
adeno-associated virus site-specific integration. Proc Natl Acad Sci 
USA 1996; 93: 7966-72. 
[219] Cortes ML, Oehmig A, Saydam O, et al. Targeted integration of 
functional human ATM cDNA into genome mediated by 
HSV/AAV hybrid amplicon vector. Mol Ther 2008; 16: 81-8. 
[220] Oehmig A, Cortes ML, Perry KF, Sena-Esteves M, Fraefel C, 
Breakefield XO. Integration of active human beta-galactosidase 
gene (100 kb) into genome using HSV/AAV amplicon vector. 
Gene Ther 2007; 14: 1078-91. 
[221] Bakowska JC, Di Maria MV, Camp SM, Wang Y, Allen PD, 
Breakefield XO. Targeted transgene integration into transgenic 
mouse fibroblasts carrying the full-length human AAVS1 locus 
mediated by HSV/AAV rep(+) hybrid amplicon vector. Gene Ther 
2003; 10: 1691-702. 
[222] Schmidt M, Afione S, Kotin RM. Adeno-associated virus type 2 
Rep78 induces apoptosis through caspase activation independently 
of p53. J Virol 2000; 74: 9441-50. 
[223] Philpott NJ, Giraud-Wali C, Dupuis C, et al. Efficient integration 
of recombinant adeno-associated virus DNA vectors requires a p5-
rep sequence in cis. J Virol 2002; 76: 5411-21. 
[224] Liu Q, Perez CF, Wang Y. Efficient site-specific integration of 
large transgenes by an enhanced herpes simplex virus/adeno-
associated virus hybrid amplicon vector. J Virol 2006; 80: 1672-9. 
[225] Philpott NJ, Gomos J, Falck-Pedersen E. Transgene expression 
after rep-mediated site-specific integration into chromosome 19. 
Hum Gene Ther 2004; 15: 47-61. 
[226] de Oliveira AP, Glauser DL, Laimbacher AS, et al. Live 
visualization of herpes simplex virus type 1 compartment 
dynamics. J Virol 2008; 82: 4974-90. 
[227] Rizzuto G, Gorgoni B, Cappelletti M, et al. Development of animal 
models for adeno-associated virus site-specific integration. J Virol 
1999; 73: 2517-26. 
[228] Dutheil N, Yoon-Robarts M, Ward P, et al. Characterization of the 
mouse adeno-associated virus AAVS1 ortholog. J Virol 2004; 78: 
8917-21. 
[229] Amiss TJ, McCarty DM, Skulimowski A, Samulski RJ. 
Identification and characterization of an adeno-associated virus 
integration site in CV-1 cells from the African green monkey. J 
Virol 2003; 77: 1904-15. 
[230] Cruchley AT, Murray PG, Niedobitek G, Reynolds GM, Williams 
DM, Young LS. The expression of the Epstein-Barr virus nuclear 
antigen (EBNA-I) in oral hairy leukoplakia. Oral Dis 1997; 3(Suppl 
1): S177-9. 
122    The Open Virology Journal, 2010, Volume 4 de Oliveira and Fraefel 
[231] Black J, Vos JM. Establishment of an oriP/EBNA1-based episomal 
vector transcribing human genomic beta-globin in cultured murine 
fibroblasts. Gene Ther 2002; 9: 1447-54. 
[232] Wang S, Vos JM. A hybrid herpesvirus infectious vector based on 
Epstein-Barr virus and herpes simplex virus type 1 for gene transfer 
into human cells in vitro and in vivo. J Virol 1996; 70: 8422-30. 
[233] Wade-Martins R, Saeki Y, Chiocca EA. Infectious delivery of a 
135-kb LDLR genomic locus leads to regulated complementation 
of low-density lipoprotein receptor deficiency in human cells. Mol 
Ther 2003; 7: 604-12. 
[234] Wade-Martins R, Smith ER, Tyminski E, Chiocca EA, Saeki Y. An 
infectious transfer and expression system for genomic DNA loci in 
human and mouse cells. Nat Biotechnol 2001; 19: 1067-70. 
[235] Wade-Martins R, Frampton J, James MR. Long-term stability of 
large insert genomic DNA episomal shuttle vectors in human cells. 
Nucleic Acids Res 1999; 27: 1674-82. 
[236] Schulz TF, Cordes S. Is the Epstein-Barr virus EBNA-1 protein an 
oncogen? Proc Natl Acad Sci USA 2009; 106: 2091-2. 
[237] Mulligan RC. The basic science of gene therapy. Science 1993; 
260: 926-32. 
[238] Nelson DM, Metzger ME, Donahue RE, Morgan RA. In vivo 
retrovirus-mediated gene transfer into multiple hematopoietic 
lineages in rabbits without preconditioning. Hum Gene Ther 1997; 
8: 747-54. 
[239] Short MP, Choi BC, Lee JK, Malick A, Breakefield XO, Martuza 
RL. Gene delivery to glioma cells in rat brain by grafting of a 
retrovirus packaging cell line. J Neurosci Res 1990; 27: 427-39. 
[240] Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese 
RM. In vivo gene transfer with retroviral vector-producer cells for 
treatment of experimental brain tumors. Science 1992; 256: 1550-2. 
[241] Takamiya Y, Short MP, Moolten FL, et al. An experimental model 
of retrovirus gene therapy for malignant brain tumors. J Neurosurg 
1993; 79: 104-10. 
[242] Isacson O, Breakefield XO. Benefits and risks of hosting animal 
cells in the human brain. Nat Med 1997; 3: 964-9. 
[243] Rainov NG. A phase III clinical evaluation of herpes simplex virus 
type 1 thymidine kinase and ganciclovir gene therapy as an 
adjuvant to surgical resection and radiation in adults with 
previously untreated glioblastoma multiforme. Hum Gene Ther 
2000; 11: 2389-401. 
[244] Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain 
tumors by intratumoral implantation of retroviral vector-producing 
cells. Nat Med 1997; 3: 1354-61. 
[245] Shand N, Weber F, Mariani L, et al. A phase 1-2 clinical trial of 
gene therapy for recurrent glioblastoma multiforme by tumor 
transduction with the herpes simplex thymidine kinase gene 
followed by ganciclovir. GLI328 European-Canadian Study Group. 
Hum Gene Ther 1999; 10: 2325-35. 
[246] Epstein AL, Manservigi R. Herpesvirus/retrovirus chimeric 
vectors. Curr Gene Ther 2004; 4: 409-16. 
[247] de Felipe P, Izquierdo M, Wandosell F, Lim F. Integrating 
retroviral cassette extends gene delivery of HSV-1 expression 
vectors to dividing cells. Biotechniques 2001; 31: 394-402, 4-5. 
[248] Hampl JA, Camp SM, Mydlarz WK, et al. Potentiated gene 
delivery to tumors using herpes simplex virus/Epstein-Barr 




Received: December 12, 2009 Revised: January 12, 2010 Accepted: January 13, 2010 
 
© de Oliveira and Fraefel; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http: //creativecommons.org/licenses/by-nc/ 






































































































































































































   '
  )2&')F ,1 )













































































  , #   -





































   




































   

  677> #






















































"    +  

 !  677> !
























   


























































































































 +	 4 6;

   8





















 +	 4 ;





 3  &) #

1  ()-28 


























  ()-28 

   






















   
 )

E"NN
)O
 

F$0(5&
**D)1
)

 
8M

"

 
8=


677>

